Breaking News

Over a week ago Show Full Stories X To view all stories in expanded form, please subscribe. Get Free Trial Send Info
Conference/Events	Force Welath to hold a webinar » 11:45 01/12/21 01/12 11:45 01/12/21 11:45 CANF Can-Fite BioPharma $1.95 / +0.045 (+2.36%) Webinar entitled,… Webinar entitled, "NASH: The Biggest Market Opportunity of 2021" consists of Can-Fite BioPharma's Dr. Fishman discussing NASH, Non-Alcoholic Fatty Liver Disease and Hepatitis C, its implications on public health and the opportunities to both control and treat the disease on January 12 at 12 pm. Webcast Link ShowHide Related Items >><< Company News Events CANF Can-Fite BioPharma $1.95 / +0.045 (+2.36%) 01/08/21 Can-Fite BioPharma announces Namodenoson study published 12/15/20 Can-Fite receives Israel Ministry of Health approval to study cannabinoids 12/14/20 Can-Fite BioPharma updates prgress with Namodenoson candidate in NAFLD 11/16/20 Can-Fite presents NASH Phase II Namodenoson da at AASLD conference 01/12/21 NASH: The Biggest Market Opportunity of 2021
Conference/Events	Force Welath to hold a webinar » 09:24 01/12/21 01/12 09:24 01/12/21 09:24 CANF Can-Fite BioPharma $1.91 / +0.015 (+0.79%) Webinar entitled,… Webinar entitled, "NASH: The Biggest Market Opportunity of 2021" consists of Can-Fite BioPharma's Dr. Fishman discussing NASH, Non-Alcoholic Fatty Liver Disease and Hepatitis C, its implications on public health and the opportunities to both control and treat the disease on January 12 at 12 pm. Webcast Link ShowHide Related Items >><< Company News Events CANF Can-Fite BioPharma $1.91 / +0.015 (+0.79%) 01/08/21 Can-Fite BioPharma announces Namodenoson study published 12/15/20 Can-Fite receives Israel Ministry of Health approval to study cannabinoids 12/14/20 Can-Fite BioPharma updates prgress with Namodenoson candidate in NAFLD 11/16/20 Can-Fite presents NASH Phase II Namodenoson da at AASLD conference 01/12/21 NASH: The Biggest Market Opportunity of 2021
Hot Stocks	Can-Fite BioPharma announces Namodenoson study published » 07:09 01/08/21 01/08 07:09 01/08/21 07:09 CANF Can-Fite BioPharma $1.88 / +0.005 (+0.27%) Can-Fite BioPharma… Can-Fite BioPharma announced a scientific paper titled, "Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial" was published in the peer reviewed journal Cancers. The paper highlights and analyzes results from Can-Fite's Phase II study, a randomized placebo-controlled trial to investigate Namodenoson as a 2nd-line treatment for advanced hepatocellular carcinoma, or HCC, and moderate hepatic dysfunction, as defined by Child-Pugh B, or CPB, scores of 7-9. Even though the trial did not meet its primary endpoint, in patients with a CPB score of 7, Namodenoson was associated with a significant improvement in 12-month overall survival and two patients are still under treatment for more than 3.5 years. A pivotal Phase III study of Namodenoson as a 2nd or 3rd line treatment in HCC CPB7 patients has been designed, and both the FDA and the European Medicines Agency, or EMA, have agreed with the protocol. Upon successful results, the trial may lead to concurrent marketing approval in the U.S. and Europe. ShowHide Related Items >><< Company News Events CANF Can-Fite BioPharma $1.88 / +0.005 (+0.27%) 12/15/20 Can-Fite receives Israel Ministry of Health approval to study cannabinoids 12/14/20 Can-Fite BioPharma updates prgress with Namodenoson candidate in NAFLD 11/16/20 Can-Fite presents NASH Phase II Namodenoson da at AASLD conference 10/06/20 IDMC recommends Can-Fite BioPharma continue Comfort trial, discontinue Acrobat 01/12/21 NASH: The Biggest Market Opportunity of 2021

Over a month ago
Hot Stocks	Can-Fite receives Israel Ministry of Health approval to study cannabinoids » 07:07 12/15/20 12/15 07:07 12/15/20 07:07 CANF Can-Fite BioPharma $1.95 / -0.02 (-1.02%) Can-Fite BioPharma… Can-Fite BioPharma announced it has received approval from the medical cannabis unit of Israel's Ministry of Health to conduct pre-clinical studies on the effect of nanomolar concentrations of cannabinoid fractions on the proliferation and functionality of cancer, inflammatory and adipocyte cells. This regulatory approval clears Can-Fite to advance its cannabinoid program by evaluating the effect of cannabis fractions at nanomolar concentrations binding with the A3 adenosine receptor, or A3AR, the target of the company's technology, in a broad range of diseases including cancer, inflammatory diseases, and metabolic diseases associated with fat accumulation. Can-Fite's recent findings show that cannabinoids can be clinically effective at minute concentrations, thereby potentially delivering efficacy without the adverse effect seen to occur with high cannabinoid concentrations as evidenced in the scientific literature. Prior pre-clinical studies jointly conducted by Can-Fite and Univo Pharmaceuticals demonstrate cannabinoid fractions inhibited liver cancer cell proliferation via A3AR. ShowHide Related Items >><< Company News CANF Can-Fite BioPharma $1.95 / -0.02 (-1.02%) 12/14/20 Can-Fite BioPharma updates prgress with Namodenoson candidate in NAFLD 11/16/20 Can-Fite presents NASH Phase II Namodenoson da at AASLD conference 10/06/20 IDMC recommends Can-Fite BioPharma continue Comfort trial, discontinue Acrobat 08/31/20 Can-Fite BioPharma cleared by FDA to commence Phase II COVID-19 study
Hot Stocks	Can-Fite BioPharma updates prgress with Namodenoson candidate in NAFLD » 07:19 12/14/20 12/14 07:19 12/14/20 07:19 CANF Can-Fite BioPharma $1.96 / +0.07 (+3.70%) Can-Fite BioPharma … Can-Fite BioPharma announced the following progress with its Namodenoson drug candidate for non-alcoholic steatohepatitis, NASH, treatment: The Company is currently engaged in the design of a Phase IIb study for Namodenoson in the treatment of NASH. The protocol is being developed in conjunction with leading Key Opinion Leaders in NASH and liver diseases including Dr. Scott Friedman, Chief of the Division of Liver Diseases at the Icahn School of Medicine at Mount Sinai in New York, and Dr. Stephen A. Harrison, Medical Director of Pinnacle Clinical Research, both of whom were involved in the design of Namodenoson's successfully completed Phase II study in NAFLD/NASH which achieved its efficacy endpoints. Drug supply - Manufacturing of Namodenoson for the upcoming clinical study has been completed. NASH patents were issued by the U.S. & European patent offices. Can-Fite's NASH clinical program is now protected by claims covering the use of the A3 adenosine receptor , the target of Can-Fite's platform technology, in reducing ectopic fat accumulation particularly in fatty liver as manifested in nonalcoholic fatty liver disease, NAFLD, and NASH. Namodenoson for the treatment of NASH is licensed for distribution in Korea and China in deals that include upfront and milestone payments. "We accumulated very important and encouraging data from our well-designed former Phase II study which successfully met its endpoints with 60 patients and determined the optimal dosage. The Phase IIb NASH protocol will dose patients with 25 mg Namodenoson and will measure several safety and efficacy endpoints including liver biopsy," stated Can-Fite CEO Dr. Pnina Fishman. ShowHide Related Items >><< Company News CANF Can-Fite BioPharma $1.96 / +0.07 (+3.70%) 11/16/20 Can-Fite presents NASH Phase II Namodenoson da at AASLD conference 10/06/20 IDMC recommends Can-Fite BioPharma continue Comfort trial, discontinue Acrobat 08/31/20 Can-Fite BioPharma cleared by FDA to commence Phase II COVID-19 study 08/25/20 Can-Fite BioPharma granted patent from EPO for Namodenoson

Hot Stocks	Can-Fite presents NASH Phase II Namodenoson da at AASLD conference » 07:10 11/16/20 11/16 07:10 11/16/20 07:10 CANF Can-Fite BioPharma $1.81 / + (+0.00%) Can-Fite… Can-Fite BioPharmannounced that Dr. Rifaat Safadi, Principal Investigator of the Company's Phase II study of Namodenoson in the treatment of NAFLD/NASH delivered a late-breaking oral presentation at the AASLD conference, The Liver Meeting Digital Experience 2020. Titled "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study Of The Efficacy And Safety Of Namodenoson , An A3 Adenosine Receptor (Agonist, In Treating Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis " the oral presentation was given on Sunday, November 15 by Dr. Safadi, Head of the Liver Unit, Gastroenterology and Liver Diseases, Division of Medicine at Hadassah Medical Center, Professor of Internal Medicine, Bowel, Liver Disease, and Metabolic Syndrome at Hebrew University in Israel. Titled "A Phase 2, Randomized, Double-Blind, Placebo-Controlled Dose-Finding Study Of The Efficacy And Safety Of Namodenoson (CF102), An A3 Adenosine Receptor (A3AR) Agonist, In Treating Non-Alcoholic Fatty Liver Disease (NAFLD) And Non-Alcoholic Steatohepatitis (NASH)" the oral presentation was given on Sunday, November 15 by Dr. Safadi, Head of the Liver Unit, Gastroenterology and Liver Diseases, Division of Medicine at Hadassah Medical Center, Professor of Internal Medicine, Bowel, Liver Disease, and Metabolic Syndrome at Hebrew University in Israel. ShowHide Related Items >><< Company News CANF Can-Fite BioPharma $1.81 / + (+0.00%) 10/06/20 IDMC recommends Can-Fite BioPharma continue Comfort trial, discontinue Acrobat 08/31/20 Can-Fite BioPharma cleared by FDA to commence Phase II COVID-19 study 08/25/20 Can-Fite BioPharma granted patent from EPO for Namodenoson 07/27/20 Can-Fite BioPharma submits IND application for Phase 2 Piclidenoson study to FDA
Conference/Events	American Association for Study of Liver Diseases to hold a virtual meeting » 04:55 11/16/20 11/16 04:55 11/16/20 04:55 ALBO Albireo Pharma $35.35 / +0.83 (+2.40%) , AZN AstraZeneca $57.37 / +0.54 (+0.95%) , BMY Bristol-Myers $63.63 / +0.88 (+1.40%) , CANF Can-Fite BioPharma $1.81 / + (+0.00%) , CBAY CymaBay $8.19 / +0.18 (+2.25%) , DNA Bought by RHHBY $0.00 / + (+0.00%) , DRRX Durect $1.79 / +0.085 (+4.99%) , ESALY Eisai $0.00 / + (+0.00%) , EXEL Exelixis $20.15 / -0.08 (-0.40%) , GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) , IVA Inventiva $14.01 / +1 (+7.69%) , MDGL Madrigal Pharmaceuticals $127.62 / +2.61 (+2.09%) , MNK Mallinckrodt $0.00 / + (+0.00%) , MRK Merck $81.10 / +1.26 (+1.58%) , MTCH Match Group $131.60 / +0.22 (+0.17%) , NVCR Novocure $124.46 / +1 (+0.81%) , RHHBY Roche $0.00 / + (+0.00%) AASLD 2020: The Virtual… AASLD 2020: The Virtual Liver Meeting will be held on November 13-16. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options RHHBY NVCR MTCH MRK MNK MDGL IVA GSK EXEL ESALY DRRX CBAY CANF BMY AZN ALBO RHHBY Roche $0.00 / + (+0.00%) 11/13/20 Halozyme: CHMP recommends EU approval of Roche's Phesgo 10/29/20 Roche receives FDA approval for cobas EGFR Mutation Test v2 10/22/20 Roche, Atea Pharmaceuticals enter agreement for exclusive rights to AT-527 10/21/20 PTC Therapeutics: Evrysdi approved in Brazil for treatment of SMA NVCR Novocure $124.46 / +1 (+0.81%) 11/11/20 Novocure receives CE Mark for NovoTTF-100L system 10/29/20 Novocure forms alliance with NYU Grossman School of Medicine 08/13/20 Novocure announces Wilco Groenhuysen as COO, other leadership promotions 07/22/20 Novocure enrolls first patient in EF-33 Phase 2 pilot trial MTCH Match Group $131.60 / +0.22 (+0.17%) 11/04/20 Match Group says future remains 'challenging to predict' 09/28/20 Match Group appoints Tracey Breeden as Head of Safety and Social Advocacy 09/03/20 Match Group says DOJ closes investigation 08/17/20 Soros boosts stakes in Alphabet, T-Mobile, takes position in Alibaba MRK Merck $81.10 / +1.26 (+1.58%) 11/15/20 Agilent receives expanded FDA approval for PD-L1 IHC 22C3 pharmDx 11/13/20 FDA approves Merck's Keytruda in combination with chemo in TNBC 11/13/20 Surface announces SRF617, SRF388 to advance to combination, expansion stages 11/11/20 Xoma earns $1M milestone payment from 2018 royalty purchase agreement MNK Mallinckrodt $0.00 / + (+0.00%) 11/10/20 Mallinckrodt initiates NOTICE study for use of INOmax gas in COVID-19 patients 10/21/20 DOJ announces settlement agreement of over $8B with opioid maker Purdue Pharma 10/12/20 Mallinckrodt voluntarily initiates Chapter 11 proceedings in bankruptcy court 10/12/20 Mallinckrodt voluntarily initiates Chapter 11 proceedings MDGL Madrigal Pharmaceuticals $127.62 / +2.61 (+2.09%) 11/13/20 Madrigal discloses data from MAESTRO-NAFLD trial ahead of AASLD presentation 10/01/20 Madrigal announces acceptance of three abstracts for The Liver Meeting 09/03/20 Madrigal exceeds target enrollment in Phase 3 MAESTRO NAFLD-1 trial 06/29/20 Intercept plunges, drags down some NASH peers after CRL from FDA IVA Inventiva $14.01 / +1 (+7.69%) 11/10/20 Inventiva announces conclusions from phase II meeting with FDA 11/06/20 Inventiva CMO Marie-Paule Richard to retire, Michael Cooreman to succeed 11/02/20 Inventiva announces publication on role of PPARs in NASH treatment 10/19/20 Inventiva gets FDA fast track designation in MPS VI for clinical stage odiparcil GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 11/09/20 GSK's ViiV says injectable cabotegravir superior to oral SOC for HIV prevention 11/02/20 Horizon Therapeutics names Karin Rosen, M.D., Ph.D. as Chief Scientific Officer 10/28/20 Sanofi, GSK to support COVAX with 200M doses of COVID-19 vaccine 10/26/20 AnaptysBio, GlaxoSmithKline amend strategic immuno-oncology collaboration EXEL Exelixis $20.15 / -0.08 (-0.40%) 10/27/20 Exelixis announces Takeda, Ono submit application for Cabometyx in Japan 10/26/20 Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo 10/19/20 Bristol-Myers, Exelixis: FDA accepts sBLA, sNDA for OPDIVO/CABOMETYX combo 10/09/20 Exelixis, Aurigene disclose new AUR102 data at ENA Symposium ESALY Eisai $0.00 / + (+0.00%) 11/10/20 Merck reports KEYTRUDA plus LENVIMA trial met primary endpoint 11/09/20 Eisai presents latest BAN2401 data at CTAD 11/06/20 Eisai down 19% as FDA panel votes on Alzheimer's drug candidate 10/30/20 Biogen announces EMA acceptance of MAA for aducanumab DRRX Durect $1.79 / +0.085 (+4.99%) 11/13/20 Durect reports new safety data and efficacy signals from Phase 1b NASH trial 11/02/20 Durect names Dr. Norman Sussman as Chief Medical Officer 10/05/20 Durect to present results from 4-week Phase 1b clinical study of DUR-928 09/23/20 Durect doses first patient in Phase 2 DUR-928 study of COVID-19 patients CBAY CymaBay $8.19 / +0.18 (+2.25%) 11/05/20 CymaBay announces study to evaluate potential of GPR119 agonists 08/27/20 CymaBay presents final results from 52-week Phase 2 study in PBC 08/20/20 CymaBay announces presentations during Digital International Liver Conference 08/03/20 CymaBay announces topline results from ENHANCE for seladelpar CANF Can-Fite BioPharma $1.81 / + (+0.00%) 10/06/20 IDMC recommends Can-Fite BioPharma continue Comfort trial, discontinue Acrobat 08/31/20 Can-Fite BioPharma cleared by FDA to commence Phase II COVID-19 study 08/25/20 Can-Fite BioPharma granted patent from EPO for Namodenoson 07/27/20 Can-Fite BioPharma submits IND application for Phase 2 Piclidenoson study to FDA BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 11/12/20 Bristol-Myers presents outcomes in 'hard to treat' blood cancers at ASH 11/09/20 Stryker appoints Giovanni Caforio to board of directors 11/09/20 Kitov expands planned Phase 1/2 clinical trial of CM24 11/09/20 Bristol-Myers: Phase 2 study evaluating deucravacitinib met primary endpoint AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/13/20 AstraZeneca announces data from U.S. hospitalized heart failure registry 11/13/20 Ionis, AstraZeneca report efficacy and safety results of antisense medicine 11/12/20 AstraZeneca says Phase 2 Calquence COVID-19 trials didn't meet primary endpoint 11/10/20 AstraZeneca, Amgen study for severe asthma meets primary endpoint ALBO Albireo Pharma $35.35 / +0.83 (+2.40%) 11/13/20 Albireo Pharma unveils novel bile acid modulators for adult liver diseases 11/13/20 Albireo Pharma announces PEDFIC 1 meets primary, secondary endpoints 09/08/20 Albireo Pharma jumps 64% after PEDFIC 1 Phase 3 trial met endpoints 09/08/20 Albireo Pharma: PEDFIC 1 Phase 3 trial met two primary endpoints ALBO AZN BMY CANF CBAY DNA DRRX ESALY EXEL GSK IVA MDGL MNK MRK MTCH NVCR RHHBY ALBO Albireo Pharma $35.35 / +0.83 (+2.40%) 09/10/20 Cowen Albireo Pharma price target raised to $65 from $39 at Cowen 09/09/20 Guggenheim Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim 09/08/20 William Blair William Blair says Albireo data confirms 'best-in-class' profile for odevixibat 09/08/20 Jefferies Albireo Pharma price target raised to $79 from $50 at Jefferies AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/11/20 Oppenheimer Amgen price target raised to $280 from $275 at Oppenheimer 11/11/20 HSBC AstraZeneca upgraded to Hold from Reduce at HSBC 11/11/20 HSBC AstraZeneca upgraded to Hold from Reduce at HSBC 10/23/20 Stifel FibroGen safety data mitigates concerns of roxadustat black box, says Stifel BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 11/10/20 Bernstein Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein 11/10/20 Bernstein Bristol-Myers initiated with a Market Perform at Bernstein 11/06/20 Gabelli Bristol-Myers downgraded to Hold from Buy at Gabelli 11/05/20 BofA BofA sees Bristol-Myers as $80 stock, 'no reason' for shares to be down CANF Can-Fite BioPharma $1.81 / + (+0.00%) CBAY CymaBay $8.19 / +0.18 (+2.25%) 11/06/20 Raymond James CymaBay price target raised to $12 at Raymond James after Q3 report 09/25/20 Piper Sandler CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler 09/09/20 B. Riley Securities CymaBay price target raised to $13 from $9 at B. Riley FBR 08/27/20 Piper Sandler Piper Sandler 'astonished' by seladelpar's long-term benefits DNA Bought by RHHBY $0.00 / + (+0.00%) DRRX Durect $1.79 / +0.085 (+4.99%) 11/03/20 Chardan Durect Covid trial update increased interest in program, says Chardan 10/30/20 Fly Intel: Top five analyst initiations 10/30/20 Chardan Durect initiated with a Buy at Chardan 10/20/20 Cantor Fitzgerald Durect assumed with an Overweight at Cantor Fitzgerald ESALY Eisai $0.00 / + (+0.00%) 11/05/20 Jefferies Eisai upgraded to Buy from Hold at Jefferies 09/08/20 Jefferies Eisai downgraded to Hold from Buy at Jefferies EXEL Exelixis $20.15 / -0.08 (-0.40%) 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler 06/30/20 Piper Sandler Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 11/13/20 Morgan Stanley GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley 11/02/20 Liberum GlaxoSmithKline upgraded to Buy from Hold at Liberum 10/30/20 Barclays GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays 10/27/20 Truist AnaptysBio price target raised to $27 from $20 at Truist IVA Inventiva $14.01 / +1 (+7.69%) 10/13/20 Roth Capital Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation 08/17/20 H.C. Wainwright Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright 08/05/20 Fly Intel: Top five analyst initiations 08/05/20 Roth Capital Inventiva initiated with a Buy at Roth Capital MDGL Madrigal Pharmaceuticals $127.62 / +2.61 (+2.09%) 11/06/20 Goldman Sachs Madrigal Pharmaceuticals price target raised to $126 from $118 at Goldman Sachs 11/06/20 Piper Sandler Piper sees 'ideal time to buy' Madrigal Pharmaceuticals ahead of AASLD meeting 11/06/20 H.C. Wainwright Madrigal Pharmaceuticals price target raised to $184 from $165 at H.C. Wainwright 11/05/20 Piper Sandler Madrigal Pharmaceuticals price target lowered to $204 from $208 at Piper Sandler MNK Mallinckrodt $0.00 / + (+0.00%) 08/06/20 Citi Mallinckrodt price target lowered to $1 from $2 at Citi 08/05/20 BMO Capital Mallinckrodt price target lowered to $2 from $4 at BMO Capital 08/04/20 Piper Sandler Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler 07/14/20 BMO Capital Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital MRK Merck $81.10 / +1.26 (+1.58%) 11/10/20 Bernstein Bernstein bullish on Merck, initiates with an Outperform 11/10/20 Bernstein Merck initiated with an Outperform at Bernstein 11/02/20 Raymond James Jounce Therapeutics downgraded to Market Perform at Raymond James 10/23/20 Fly Intel: Pre-market Movers MTCH Match Group $131.60 / +0.22 (+0.17%) 11/10/20 Truist Match Group price target raised to $150 from $125 at Truist 11/10/20 Deutsche Bank Match Group price target raised to $160 from $150 at Deutsche Bank 11/09/20 Citi Match Group price target raised to $160 from $135 at Citi 09/24/20 Jefferies Match Group positioned to take advantage of pent up demand, says Jefferies NVCR Novocure $124.46 / +1 (+0.81%) 10/30/20 Mizuho Novocure price target raised to $150 from $84 at Mizuho 10/29/20 Piper Sandler Novocure price target raised to $140 from $125 at Piper Sandler 10/05/20 Piper Sandler Bristol-Myers approval removes some Novocure revenue upside, says Piper Sandler 09/23/20 Fly Intel: Top five analyst initiations RHHBY Roche $0.00 / + (+0.00%) 11/11/20 Truist Opthea initiated with a Buy at Truist 10/16/20 UBS Roche price target lowered to CHF 370 from CHF 390 at UBS 10/06/20 Goldman Sachs Goldman reiterates $34 target on Kiniksa after 'impressive' data 09/29/20 Berenberg Roche initiated with a Hold at Berenberg RHHBY NVCR MTCH MRK MNK MDGL GSK EXEL DRRX CBAY BMY AZN ALBO RHHBY Roche $0.00 / + (+0.00%) 10/27/20 Oncolytics announces new GI cancer study using 10/15/20 Roche confirms outlook for 2020 based on assessment of COVID-19 10/15/20 Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year 09/11/20 Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS NVCR Novocure $124.46 / +1 (+0.81%) 10/29/20 Novocure reports Q3 EPS 9c, consensus 3c 07/30/20 Novocure reports Q2 EPS 2c, consensus 0c MTCH Match Group $131.60 / +0.22 (+0.17%) 11/04/20 Match Group sees Q4 revenue $640M-$650M, consensus $622.73M 11/04/20 Match Group report Q3 EPS 45c, consensus 44c 11/04/20 Notable companies reporting after market close 08/10/20 IAC reports Q2 EPS ($1.13) vs. 16c a year ago MRK Merck $81.10 / +1.26 (+1.58%) 10/27/20 Merck raises FY20 adjusted EPS view to $5.91-$6.01 from $5.63-$5.78 10/27/20 Merck reports Q3 adjusted EPS $1.74, consensus $1.43 10/26/20 Notable companies reporting before tomorrow's open MNK Mallinckrodt $0.00 / + (+0.00%) 08/04/20 Mallinckrodt reports Q2 adj. EPS $1.89, consensus $1.34 MDGL Madrigal Pharmaceuticals $127.62 / +2.61 (+2.09%) 11/05/20 Madrigal Pharmaceuticals reports Q3 EPS ($3.75), consensus ($3.30) 08/06/20 Madrigal Pharmaceuticals reports Q2 EPS ($3.18), consensus ($2.45) GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 10/28/20 GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range 10/28/20 GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago 10/08/20 GlaxoSmithKline sees impact of foreign exchange on Q3 sales of about 5% 07/29/20 GlaxoSmithKline reports Q2 adjusted EPS 19.2p, down 37% AER EXEL Exelixis $20.15 / -0.08 (-0.40%) 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c 08/06/20 Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M 08/06/20 Exelixis reports Q2 EPS 25c, consensus 12c DRRX Durect $1.79 / +0.085 (+4.99%) 11/02/20 Durect reports Q3 EPS (5c), consensus (4c) 08/03/20 Durect reports Q2 EPS 7c, consensus 0c CBAY CymaBay $8.19 / +0.18 (+2.25%) 11/05/20 CymaBay reports Q3 EPS (17c), consensus (17c) 08/10/20 CymaBay reports Q2 EPS (16c), consensus (24c) BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 11/05/20 Bristol-Myers backs FY21 EPS view $7.15-$7.45, consensus $7.39 11/05/20 Bristol-Myers raises FY20 EPS view to $6.25-$6.35 from $6.10-$6.25 11/05/20 Bristol-Myers reports Q3 EPS $1.63, consensus $1.49 11/04/20 Notable companies reporting before tomorrow's open AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER ALBO Albireo Pharma $35.35 / +0.83 (+2.40%) 11/05/20 Albireo Pharma reports Q3 EPS ($1.96), consensus ($1.51) 08/06/20 Albireo Pharma reports Q2 EPS ($1.38), consensus ($1.69) 10 Sep 10 Jul 30 Jan 11 Dec RHHBY MTCH MRK MNK GSK BMY AZN RHHBY Roche $0.00 / + (+0.00%) 11/11/20 Roche's Franz favors COVID-19 vaccination mandate, Reuters says 10/07/20 Roche warehouse issue causes diagnostic test shipping delays, Bloomberg reports MTCH Match Group $131.60 / +0.22 (+0.17%) 09/24/20 Spotify, Match, Epic join forces to challenge App Store practices, Reuters says 08/17/20 Facebook backs Fortnite in Apple app fee battle, NY Post says 08/11/20 Match Group developing interactive features for users, WSJ reports 06/17/20 Match, Epic vocalize support for EU antitrust case against Apple, Verge says MRK Merck $81.10 / +1.26 (+1.58%) 09/24/20 Merck Covid vaccines match 'Operation Warp Speed' description, Bloomberg says 09/11/20 Merck begins testing COVID-19 vaccine in humans in phase 1/2 trial, WSJ reports MNK Mallinckrodt $0.00 / + (+0.00%) 10/21/20 Purdue Pharma to plead guilty in $8B-plus deal, AP reports 09/25/20 Mallinckrodt nearing bankruptcy filing, negotiating with key creditors, WSJ says 09/25/20 Mallinckrodt nearing bankruptcy filing over opioid suits, WSJ says GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 10/02/20 White House officials raise objections to FDA vaccine approval plans, WSJ says 10/02/20 GlaxoSmithKline verdict of $235M against Teva revived on appeal, Bloomberg says 09/23/20 U.K. to test vaccines on volunteers deliberately infected with COVID, FT reports 09/22/20 FDA to announce tougher standards for coronavirus vaccine, WaPo says BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 10/05/20 Bristol-Myers to buy MyoKardia for $13.1B, or $225/share in cash, WSJ reports 08/06/20 Trump to order government to buy certain drugs from U.S., USA Today says 07/24/20 President Trump expected to sign drug pricing executive orders, WaPo reports AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/09/20 Pfizer in talks with Brazil about selling COVID vaccine, Reuters says 11/04/20 AstraZeneca misses COVID-19 vaccine delivery target in UK, FT says 11/03/20 UK's NHS told to prepare for possible vaccine rollout as early as Dec., Sky says 10/26/20 AstraZeneca vaccine candidate shows robust immune response in elderly, FT says RHHBY MTCH MRK MNK MDGL IVA GSK ESALY DRRX CBAY BMY AZN ALBO RHHBY Roche $0.00 / + (+0.00%) 09/29/20 Hersey, Best Buy upgrades among today's top calls on Wall Street 09/23/20 Fly Intel: Wall Street's top stories for Wednesday 09/23/20 Fly Intel: Wall Street's top stories at midday 09/23/20 Regenxbio slips as Novartis' Zolgensma expansion hits FDA roadblock MTCH Match Group $131.60 / +0.22 (+0.17%) 11/04/20 Fly Intel: After-Hours Movers 09/24/20 Fly Intel: Wall Street's top stories for Thursday 09/24/20 Fly Intel: Wall Street's top stories at midday 09/03/20 Fly Intel: After-Hours Movers MRK Merck $81.10 / +1.26 (+1.58%) 10/27/20 Fly Intel: Wall Street's top stories for Tuesday 10/27/20 Fly Intel: Wall Street's top stories at midday 10/27/20 Fly Intel: Pre-market Movers MNK Mallinckrodt $0.00 / + (+0.00%) 07/15/20 Fly Intel: After-Hours Movers MDGL Madrigal Pharmaceuticals $127.62 / +2.61 (+2.09%) 11/12/20 Before the Move: Watch Madrigal Pharmaceuticals ahead of AASLD meeting IVA Inventiva $14.01 / +1 (+7.69%) 10/19/20 Fly Intel: After-Hours Movers 10/12/20 Fly Intel: After-Hours Movers GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 10/06/20 Fly Intel: Wall Street's top stories for Tuesday 10/06/20 Fly Intel: Wall Street's top stories at midday 09/19/20 Week in review: How Trump's policies moved stocks ESALY Eisai $0.00 / + (+0.00%) 08/07/20 Fly Intel: Wall Street's top stories at midday DRRX Durect $1.79 / +0.085 (+4.99%) 11/03/20 Fly Intel: Pre-market Movers 11/02/20 Fly Intel: After-Hours Movers 08/03/20 Fly Intel: After-Hours Movers 07/31/20 Fly Intel: Alphabet downgrade among today's top calls on Wall Street CBAY CymaBay $8.19 / +0.18 (+2.25%) 08/10/20 Fly Intel: After-Hours Movers 06/29/20 Fly Intel: Pre-market Movers BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 11/05/20 Fly Intel: Pre-market Movers 10/08/20 Cytokinetics plunges following mixed results from heart drug trial 10/05/20 Fly Intel: Wall Street's top stories for Monday 10/05/20 Fly Intel: Wall Street's top stories at midday AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/12/20 Fly Intel: Wall Street's top stories for Thursday 11/12/20 Fly Intel: Wall Street's top stories at midday 11/04/20 Fly Intel: Wall Street's top stories for Wednesday 10/23/20 Fly Intel: Wall Street's top stories for Friday ALBO Albireo Pharma $35.35 / +0.83 (+2.40%) 09/30/20 Before the Move: Watch Novo Nordisk, Bristol into AASLD abstract publication 09/08/20 Fly Intel: Wall Street's top stories at midday 12/15/20 Biopharmaceuticals/Biotech 11/17/20 West Coast Consumer Virtual Conference 11/19/20 2nd Annual Virtual Healthcare Conference 12/06/20 62nd Virtual Annual Meeting of ASH 12/08/20 Global TMT Virtual Conference 11/16/20 Inventiva - IVA 02/04/21 Merck - MRK 11/16/20 PDUFA Date for Lisocabtagene Maraleucel (liso-cel) 11/23/20 PDUFA Date for Xofluza 02/02/21 PDUFA Date for StrataGraft 02/20/21 PDUFA Date for OPDIVO / CABOMETYX bmy 03/27/21 PDUFA Date for Ide-Cel 11/23/20 Durect MTCH MRK MNK GSK DRRX CBAY BMY AZN MTCH Match Group $131.60 / +0.22 (+0.17%) 07/28/20 Match Group call volume above normal and directionally bullish 07/09/20 Unusually active option classes on open July 9th 06/23/20 Largest borrow rate increases among liquid names 06/22/20 Largest borrow rate increases among liquid names MRK Merck $81.10 / +1.26 (+1.58%) 10/20/20 Merck put volume heavy and directionally bearish 08/05/20 Merck call volume above normal and directionally bullish 08/05/20 Unusually active option classes on open August 5th MNK Mallinckrodt $0.00 / + (+0.00%) 10/13/20 Three new option listings and three option delistings on October 13th 10/08/20 Largest borrow rate increases among liquid names 08/25/20 Largest borrow rate increases among liquid names 08/20/20 Largest borrow rate increases among liquid names GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 09/04/20 GlaxoSmithKline call volume above normal and directionally bullish 08/03/20 Unusually active option classes on open August 3rd 07/31/20 Unusually active option classes on open July 31st 07/16/20 GlaxoSmithKline put volume heavy and directionally bearish DRRX Durect $1.79 / +0.085 (+4.99%) 08/03/20 Durect options imply 25.4% move in share price post-earnings CBAY CymaBay $8.19 / +0.18 (+2.25%) 11/13/20 Largest borrow rate increases among liquid names 06/16/20 Unusual call flow in option market yesterday 06/15/20 Cymabay calls lead puts 20:1 as shares lift 10% and implied volatility BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 11/04/20 Unusually active option classes on open November 4th 09/25/20 Unusually active option classes on open September 25th 08/06/20 Unusually active option classes on open August 6th AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/10/20 Largest borrow rate increases among liquid names 11/03/20 Unusually active option classes on open November 3rd 10/26/20 Unusually active option classes on open October 26th 09/09/20 Unusually active option classes on open September 9th
Conference/Events	American Association for Study of Liver Diseases to hold a virtual meeting » 04:55 11/15/20 11/15 04:55 11/15/20 04:55 ALBO Albireo Pharma $35.35 / +0.83 (+2.40%) , AZN AstraZeneca $57.37 / +0.54 (+0.95%) , BMY Bristol-Myers $63.63 / +0.88 (+1.40%) , CANF Can-Fite BioPharma $1.81 / + (+0.00%) , CBAY CymaBay $8.19 / +0.18 (+2.25%) , DNA Bought by RHHBY $0.00 / + (+0.00%) , DRRX Durect $1.79 / +0.085 (+4.99%) , ESALY Eisai $0.00 / + (+0.00%) , EXEL Exelixis $20.15 / -0.08 (-0.40%) , GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) , IVA Inventiva $14.01 / +1 (+7.69%) , MDGL Madrigal Pharmaceuticals $127.62 / +2.61 (+2.09%) , MNK Mallinckrodt $0.00 / + (+0.00%) , MRK Merck $81.10 / +1.26 (+1.58%) , MTCH Match Group $131.60 / +0.22 (+0.17%) , NVCR Novocure $124.46 / +1 (+0.81%) , RHHBY Roche $0.00 / + (+0.00%) AASLD 2020: The Virtual… AASLD 2020: The Virtual Liver Meeting will be held on November 13-16. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options RHHBY NVCR MTCH MRK MNK MDGL IVA GSK EXEL ESALY DRRX CBAY CANF BMY AZN ALBO RHHBY Roche $0.00 / + (+0.00%) 11/13/20 Halozyme: CHMP recommends EU approval of Roche's Phesgo 10/29/20 Roche receives FDA approval for cobas EGFR Mutation Test v2 10/22/20 Roche, Atea Pharmaceuticals enter agreement for exclusive rights to AT-527 10/21/20 PTC Therapeutics: Evrysdi approved in Brazil for treatment of SMA NVCR Novocure $124.46 / +1 (+0.81%) 11/11/20 Novocure receives CE Mark for NovoTTF-100L system 10/29/20 Novocure forms alliance with NYU Grossman School of Medicine 08/13/20 Novocure announces Wilco Groenhuysen as COO, other leadership promotions 07/22/20 Novocure enrolls first patient in EF-33 Phase 2 pilot trial MTCH Match Group $131.60 / +0.22 (+0.17%) 11/04/20 Match Group says future remains 'challenging to predict' 09/28/20 Match Group appoints Tracey Breeden as Head of Safety and Social Advocacy 09/03/20 Match Group says DOJ closes investigation 08/17/20 Soros boosts stakes in Alphabet, T-Mobile, takes position in Alibaba MRK Merck $81.10 / +1.26 (+1.58%) 11/13/20 FDA approves Merck's Keytruda in combination with chemo in TNBC 11/13/20 Surface announces SRF617, SRF388 to advance to combination, expansion stages 11/11/20 Xoma earns $1M milestone payment from 2018 royalty purchase agreement 11/11/20 Moderna shares interim data from mRNA-4157 with Keytruda cohort at SITC MNK Mallinckrodt $0.00 / + (+0.00%) 11/10/20 Mallinckrodt initiates NOTICE study for use of INOmax gas in COVID-19 patients 10/21/20 DOJ announces settlement agreement of over $8B with opioid maker Purdue Pharma 10/12/20 Mallinckrodt voluntarily initiates Chapter 11 proceedings in bankruptcy court 10/12/20 Mallinckrodt voluntarily initiates Chapter 11 proceedings MDGL Madrigal Pharmaceuticals $127.62 / +2.61 (+2.09%) 11/13/20 Madrigal discloses data from MAESTRO-NAFLD trial ahead of AASLD presentation 10/01/20 Madrigal announces acceptance of three abstracts for The Liver Meeting 09/03/20 Madrigal exceeds target enrollment in Phase 3 MAESTRO NAFLD-1 trial 06/29/20 Intercept plunges, drags down some NASH peers after CRL from FDA IVA Inventiva $14.01 / +1 (+7.69%) 11/10/20 Inventiva announces conclusions from phase II meeting with FDA 11/06/20 Inventiva CMO Marie-Paule Richard to retire, Michael Cooreman to succeed 11/02/20 Inventiva announces publication on role of PPARs in NASH treatment 10/19/20 Inventiva gets FDA fast track designation in MPS VI for clinical stage odiparcil GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 11/09/20 GSK's ViiV says injectable cabotegravir superior to oral SOC for HIV prevention 11/02/20 Horizon Therapeutics names Karin Rosen, M.D., Ph.D. as Chief Scientific Officer 10/28/20 Sanofi, GSK to support COVAX with 200M doses of COVID-19 vaccine 10/26/20 AnaptysBio, GlaxoSmithKline amend strategic immuno-oncology collaboration EXEL Exelixis $20.15 / -0.08 (-0.40%) 10/27/20 Exelixis announces Takeda, Ono submit application for Cabometyx in Japan 10/26/20 Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo 10/19/20 Bristol-Myers, Exelixis: FDA accepts sBLA, sNDA for OPDIVO/CABOMETYX combo 10/09/20 Exelixis, Aurigene disclose new AUR102 data at ENA Symposium ESALY Eisai $0.00 / + (+0.00%) 11/10/20 Merck reports KEYTRUDA plus LENVIMA trial met primary endpoint 11/09/20 Eisai presents latest BAN2401 data at CTAD 11/06/20 Eisai down 19% as FDA panel votes on Alzheimer's drug candidate 10/30/20 Biogen announces EMA acceptance of MAA for aducanumab DRRX Durect $1.79 / +0.085 (+4.99%) 11/13/20 Durect reports new safety data and efficacy signals from Phase 1b NASH trial 11/02/20 Durect names Dr. Norman Sussman as Chief Medical Officer 10/05/20 Durect to present results from 4-week Phase 1b clinical study of DUR-928 09/23/20 Durect doses first patient in Phase 2 DUR-928 study of COVID-19 patients CBAY CymaBay $8.19 / +0.18 (+2.25%) 11/05/20 CymaBay announces study to evaluate potential of GPR119 agonists 08/27/20 CymaBay presents final results from 52-week Phase 2 study in PBC 08/20/20 CymaBay announces presentations during Digital International Liver Conference 08/03/20 CymaBay announces topline results from ENHANCE for seladelpar CANF Can-Fite BioPharma $1.81 / + (+0.00%) 10/06/20 IDMC recommends Can-Fite BioPharma continue Comfort trial, discontinue Acrobat 08/31/20 Can-Fite BioPharma cleared by FDA to commence Phase II COVID-19 study 08/25/20 Can-Fite BioPharma granted patent from EPO for Namodenoson 07/27/20 Can-Fite BioPharma submits IND application for Phase 2 Piclidenoson study to FDA BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 11/12/20 Bristol-Myers presents outcomes in 'hard to treat' blood cancers at ASH 11/09/20 Stryker appoints Giovanni Caforio to board of directors 11/09/20 Kitov expands planned Phase 1/2 clinical trial of CM24 11/09/20 Bristol-Myers: Phase 2 study evaluating deucravacitinib met primary endpoint AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/13/20 AstraZeneca announces data from U.S. hospitalized heart failure registry 11/13/20 Ionis, AstraZeneca report efficacy and safety results of antisense medicine 11/12/20 AstraZeneca says Phase 2 Calquence COVID-19 trials didn't meet primary endpoint 11/10/20 AstraZeneca, Amgen study for severe asthma meets primary endpoint ALBO Albireo Pharma $35.35 / +0.83 (+2.40%) 11/13/20 Albireo Pharma unveils novel bile acid modulators for adult liver diseases 11/13/20 Albireo Pharma announces PEDFIC 1 meets primary, secondary endpoints 09/08/20 Albireo Pharma jumps 64% after PEDFIC 1 Phase 3 trial met endpoints 09/08/20 Albireo Pharma: PEDFIC 1 Phase 3 trial met two primary endpoints ALBO AZN BMY CANF CBAY DNA DRRX ESALY EXEL GSK IVA MDGL MNK MRK MTCH NVCR RHHBY ALBO Albireo Pharma $35.35 / +0.83 (+2.40%) 09/10/20 Cowen Albireo Pharma price target raised to $65 from $39 at Cowen 09/09/20 Guggenheim Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim 09/08/20 William Blair William Blair says Albireo data confirms 'best-in-class' profile for odevixibat 09/08/20 Jefferies Albireo Pharma price target raised to $79 from $50 at Jefferies AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/11/20 Oppenheimer Amgen price target raised to $280 from $275 at Oppenheimer 11/11/20 HSBC AstraZeneca upgraded to Hold from Reduce at HSBC 11/11/20 HSBC AstraZeneca upgraded to Hold from Reduce at HSBC 10/23/20 Stifel FibroGen safety data mitigates concerns of roxadustat black box, says Stifel BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 11/10/20 Bernstein Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein 11/10/20 Bernstein Bristol-Myers initiated with a Market Perform at Bernstein 11/06/20 Gabelli Bristol-Myers downgraded to Hold from Buy at Gabelli 11/05/20 BofA BofA sees Bristol-Myers as $80 stock, 'no reason' for shares to be down CANF Can-Fite BioPharma $1.81 / + (+0.00%) CBAY CymaBay $8.19 / +0.18 (+2.25%) 11/06/20 Raymond James CymaBay price target raised to $12 at Raymond James after Q3 report 09/25/20 Piper Sandler CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler 09/09/20 B. Riley Securities CymaBay price target raised to $13 from $9 at B. Riley FBR 08/27/20 Piper Sandler Piper Sandler 'astonished' by seladelpar's long-term benefits DNA Bought by RHHBY $0.00 / + (+0.00%) DRRX Durect $1.79 / +0.085 (+4.99%) 11/03/20 Chardan Durect Covid trial update increased interest in program, says Chardan 10/30/20 Fly Intel: Top five analyst initiations 10/30/20 Chardan Durect initiated with a Buy at Chardan 10/20/20 Cantor Fitzgerald Durect assumed with an Overweight at Cantor Fitzgerald ESALY Eisai $0.00 / + (+0.00%) 11/05/20 Jefferies Eisai upgraded to Buy from Hold at Jefferies 09/08/20 Jefferies Eisai downgraded to Hold from Buy at Jefferies EXEL Exelixis $20.15 / -0.08 (-0.40%) 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler 06/30/20 Piper Sandler Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 11/13/20 Morgan Stanley GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley 11/02/20 Liberum GlaxoSmithKline upgraded to Buy from Hold at Liberum 10/30/20 Barclays GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays 10/27/20 Truist AnaptysBio price target raised to $27 from $20 at Truist IVA Inventiva $14.01 / +1 (+7.69%) 10/13/20 Roth Capital Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation 08/17/20 H.C. Wainwright Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright 08/05/20 Fly Intel: Top five analyst initiations 08/05/20 Roth Capital Inventiva initiated with a Buy at Roth Capital MDGL Madrigal Pharmaceuticals $127.62 / +2.61 (+2.09%) 11/06/20 Goldman Sachs Madrigal Pharmaceuticals price target raised to $126 from $118 at Goldman Sachs 11/06/20 Piper Sandler Piper sees 'ideal time to buy' Madrigal Pharmaceuticals ahead of AASLD meeting 11/06/20 H.C. Wainwright Madrigal Pharmaceuticals price target raised to $184 from $165 at H.C. Wainwright 11/05/20 Piper Sandler Madrigal Pharmaceuticals price target lowered to $204 from $208 at Piper Sandler MNK Mallinckrodt $0.00 / + (+0.00%) 08/06/20 Citi Mallinckrodt price target lowered to $1 from $2 at Citi 08/05/20 BMO Capital Mallinckrodt price target lowered to $2 from $4 at BMO Capital 08/04/20 Piper Sandler Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler 07/14/20 BMO Capital Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital MRK Merck $81.10 / +1.26 (+1.58%) 11/10/20 Bernstein Bernstein bullish on Merck, initiates with an Outperform 11/10/20 Bernstein Merck initiated with an Outperform at Bernstein 11/02/20 Raymond James Jounce Therapeutics downgraded to Market Perform at Raymond James 10/23/20 Fly Intel: Pre-market Movers MTCH Match Group $131.60 / +0.22 (+0.17%) 11/10/20 Truist Match Group price target raised to $150 from $125 at Truist 11/10/20 Deutsche Bank Match Group price target raised to $160 from $150 at Deutsche Bank 11/09/20 Citi Match Group price target raised to $160 from $135 at Citi 09/24/20 Jefferies Match Group positioned to take advantage of pent up demand, says Jefferies NVCR Novocure $124.46 / +1 (+0.81%) 10/30/20 Mizuho Novocure price target raised to $150 from $84 at Mizuho 10/29/20 Piper Sandler Novocure price target raised to $140 from $125 at Piper Sandler 10/05/20 Piper Sandler Bristol-Myers approval removes some Novocure revenue upside, says Piper Sandler 09/23/20 Fly Intel: Top five analyst initiations RHHBY Roche $0.00 / + (+0.00%) 11/11/20 Truist Opthea initiated with a Buy at Truist 10/16/20 UBS Roche price target lowered to CHF 370 from CHF 390 at UBS 10/06/20 Goldman Sachs Goldman reiterates $34 target on Kiniksa after 'impressive' data 09/29/20 Berenberg Roche initiated with a Hold at Berenberg RHHBY NVCR MTCH MRK MNK MDGL GSK EXEL DRRX CBAY BMY AZN ALBO RHHBY Roche $0.00 / + (+0.00%) 10/27/20 Oncolytics announces new GI cancer study using 10/15/20 Roche confirms outlook for 2020 based on assessment of COVID-19 10/15/20 Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year 09/11/20 Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS NVCR Novocure $124.46 / +1 (+0.81%) 10/29/20 Novocure reports Q3 EPS 9c, consensus 3c 07/30/20 Novocure reports Q2 EPS 2c, consensus 0c MTCH Match Group $131.60 / +0.22 (+0.17%) 11/04/20 Match Group sees Q4 revenue $640M-$650M, consensus $622.73M 11/04/20 Match Group report Q3 EPS 45c, consensus 44c 11/04/20 Notable companies reporting after market close 08/10/20 IAC reports Q2 EPS ($1.13) vs. 16c a year ago MRK Merck $81.10 / +1.26 (+1.58%) 10/27/20 Merck raises FY20 adjusted EPS view to $5.91-$6.01 from $5.63-$5.78 10/27/20 Merck reports Q3 adjusted EPS $1.74, consensus $1.43 10/26/20 Notable companies reporting before tomorrow's open MNK Mallinckrodt $0.00 / + (+0.00%) 08/04/20 Mallinckrodt reports Q2 adj. EPS $1.89, consensus $1.34 MDGL Madrigal Pharmaceuticals $127.62 / +2.61 (+2.09%) 11/05/20 Madrigal Pharmaceuticals reports Q3 EPS ($3.75), consensus ($3.30) 08/06/20 Madrigal Pharmaceuticals reports Q2 EPS ($3.18), consensus ($2.45) GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 10/28/20 GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range 10/28/20 GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago 10/08/20 GlaxoSmithKline sees impact of foreign exchange on Q3 sales of about 5% 07/29/20 GlaxoSmithKline reports Q2 adjusted EPS 19.2p, down 37% AER EXEL Exelixis $20.15 / -0.08 (-0.40%) 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c 08/06/20 Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M 08/06/20 Exelixis reports Q2 EPS 25c, consensus 12c DRRX Durect $1.79 / +0.085 (+4.99%) 11/02/20 Durect reports Q3 EPS (5c), consensus (4c) 08/03/20 Durect reports Q2 EPS 7c, consensus 0c CBAY CymaBay $8.19 / +0.18 (+2.25%) 11/05/20 CymaBay reports Q3 EPS (17c), consensus (17c) 08/10/20 CymaBay reports Q2 EPS (16c), consensus (24c) BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 11/05/20 Bristol-Myers backs FY21 EPS view $7.15-$7.45, consensus $7.39 11/05/20 Bristol-Myers raises FY20 EPS view to $6.25-$6.35 from $6.10-$6.25 11/05/20 Bristol-Myers reports Q3 EPS $1.63, consensus $1.49 11/04/20 Notable companies reporting before tomorrow's open AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER ALBO Albireo Pharma $35.35 / +0.83 (+2.40%) 11/05/20 Albireo Pharma reports Q3 EPS ($1.96), consensus ($1.51) 08/06/20 Albireo Pharma reports Q2 EPS ($1.38), consensus ($1.69) 10 Sep 10 Jul 30 Jan 11 Dec RHHBY MTCH MRK MNK GSK BMY AZN RHHBY Roche $0.00 / + (+0.00%) 11/11/20 Roche's Franz favors COVID-19 vaccination mandate, Reuters says 10/07/20 Roche warehouse issue causes diagnostic test shipping delays, Bloomberg reports MTCH Match Group $131.60 / +0.22 (+0.17%) 09/24/20 Spotify, Match, Epic join forces to challenge App Store practices, Reuters says 08/17/20 Facebook backs Fortnite in Apple app fee battle, NY Post says 08/11/20 Match Group developing interactive features for users, WSJ reports 06/17/20 Match, Epic vocalize support for EU antitrust case against Apple, Verge says MRK Merck $81.10 / +1.26 (+1.58%) 09/24/20 Merck Covid vaccines match 'Operation Warp Speed' description, Bloomberg says 09/11/20 Merck begins testing COVID-19 vaccine in humans in phase 1/2 trial, WSJ reports MNK Mallinckrodt $0.00 / + (+0.00%) 10/21/20 Purdue Pharma to plead guilty in $8B-plus deal, AP reports 09/25/20 Mallinckrodt nearing bankruptcy filing, negotiating with key creditors, WSJ says 09/25/20 Mallinckrodt nearing bankruptcy filing over opioid suits, WSJ says GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 10/02/20 White House officials raise objections to FDA vaccine approval plans, WSJ says 10/02/20 GlaxoSmithKline verdict of $235M against Teva revived on appeal, Bloomberg says 09/23/20 U.K. to test vaccines on volunteers deliberately infected with COVID, FT reports 09/22/20 FDA to announce tougher standards for coronavirus vaccine, WaPo says BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 10/05/20 Bristol-Myers to buy MyoKardia for $13.1B, or $225/share in cash, WSJ reports 08/06/20 Trump to order government to buy certain drugs from U.S., USA Today says 07/24/20 President Trump expected to sign drug pricing executive orders, WaPo reports AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/09/20 Pfizer in talks with Brazil about selling COVID vaccine, Reuters says 11/04/20 AstraZeneca misses COVID-19 vaccine delivery target in UK, FT says 11/03/20 UK's NHS told to prepare for possible vaccine rollout as early as Dec., Sky says 10/26/20 AstraZeneca vaccine candidate shows robust immune response in elderly, FT says RHHBY MTCH MRK MNK MDGL IVA GSK ESALY DRRX CBAY BMY AZN ALBO RHHBY Roche $0.00 / + (+0.00%) 09/29/20 Hersey, Best Buy upgrades among today's top calls on Wall Street 09/23/20 Fly Intel: Wall Street's top stories for Wednesday 09/23/20 Fly Intel: Wall Street's top stories at midday 09/23/20 Regenxbio slips as Novartis' Zolgensma expansion hits FDA roadblock MTCH Match Group $131.60 / +0.22 (+0.17%) 11/04/20 Fly Intel: After-Hours Movers 09/24/20 Fly Intel: Wall Street's top stories for Thursday 09/24/20 Fly Intel: Wall Street's top stories at midday 09/03/20 Fly Intel: After-Hours Movers MRK Merck $81.10 / +1.26 (+1.58%) 10/27/20 Fly Intel: Wall Street's top stories for Tuesday 10/27/20 Fly Intel: Wall Street's top stories at midday 10/27/20 Fly Intel: Pre-market Movers MNK Mallinckrodt $0.00 / + (+0.00%) 07/15/20 Fly Intel: After-Hours Movers MDGL Madrigal Pharmaceuticals $127.62 / +2.61 (+2.09%) 11/12/20 Before the Move: Watch Madrigal Pharmaceuticals ahead of AASLD meeting IVA Inventiva $14.01 / +1 (+7.69%) 10/19/20 Fly Intel: After-Hours Movers 10/12/20 Fly Intel: After-Hours Movers GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 10/06/20 Fly Intel: Wall Street's top stories for Tuesday 10/06/20 Fly Intel: Wall Street's top stories at midday 09/19/20 Week in review: How Trump's policies moved stocks ESALY Eisai $0.00 / + (+0.00%) 08/07/20 Fly Intel: Wall Street's top stories at midday DRRX Durect $1.79 / +0.085 (+4.99%) 11/03/20 Fly Intel: Pre-market Movers 11/02/20 Fly Intel: After-Hours Movers 08/03/20 Fly Intel: After-Hours Movers 07/31/20 Fly Intel: Alphabet downgrade among today's top calls on Wall Street CBAY CymaBay $8.19 / +0.18 (+2.25%) 08/10/20 Fly Intel: After-Hours Movers 06/29/20 Fly Intel: Pre-market Movers BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 11/05/20 Fly Intel: Pre-market Movers 10/08/20 Cytokinetics plunges following mixed results from heart drug trial 10/05/20 Fly Intel: Wall Street's top stories for Monday 10/05/20 Fly Intel: Wall Street's top stories at midday AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/12/20 Fly Intel: Wall Street's top stories for Thursday 11/12/20 Fly Intel: Wall Street's top stories at midday 11/04/20 Fly Intel: Wall Street's top stories for Wednesday 10/23/20 Fly Intel: Wall Street's top stories for Friday ALBO Albireo Pharma $35.35 / +0.83 (+2.40%) 09/30/20 Before the Move: Watch Novo Nordisk, Bristol into AASLD abstract publication 09/08/20 Fly Intel: Wall Street's top stories at midday 12/15/20 Biopharmaceuticals/Biotech 11/17/20 West Coast Consumer Virtual Conference 11/19/20 2nd Annual Virtual Healthcare Conference 12/06/20 62nd Virtual Annual Meeting of ASH 12/08/20 Global TMT Virtual Conference 11/16/20 Inventiva - IVA 02/04/21 Merck - MRK 11/23/20 PDUFA Date for Xofluza 02/02/21 PDUFA Date for StrataGraft 02/20/21 PDUFA Date for OPDIVO / CABOMETYX bmy 03/27/21 PDUFA Date for Ide-Cel 11/23/20 Durect MTCH MRK MNK GSK DRRX CBAY BMY AZN MTCH Match Group $131.60 / +0.22 (+0.17%) 07/28/20 Match Group call volume above normal and directionally bullish 07/09/20 Unusually active option classes on open July 9th 06/23/20 Largest borrow rate increases among liquid names 06/22/20 Largest borrow rate increases among liquid names MRK Merck $81.10 / +1.26 (+1.58%) 10/20/20 Merck put volume heavy and directionally bearish 08/05/20 Merck call volume above normal and directionally bullish 08/05/20 Unusually active option classes on open August 5th MNK Mallinckrodt $0.00 / + (+0.00%) 10/13/20 Three new option listings and three option delistings on October 13th 10/08/20 Largest borrow rate increases among liquid names 08/25/20 Largest borrow rate increases among liquid names 08/20/20 Largest borrow rate increases among liquid names GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 09/04/20 GlaxoSmithKline call volume above normal and directionally bullish 08/03/20 Unusually active option classes on open August 3rd 07/31/20 Unusually active option classes on open July 31st 07/16/20 GlaxoSmithKline put volume heavy and directionally bearish DRRX Durect $1.79 / +0.085 (+4.99%) 08/03/20 Durect options imply 25.4% move in share price post-earnings CBAY CymaBay $8.19 / +0.18 (+2.25%) 11/13/20 Largest borrow rate increases among liquid names 06/16/20 Unusual call flow in option market yesterday 06/15/20 Cymabay calls lead puts 20:1 as shares lift 10% and implied volatility BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 11/04/20 Unusually active option classes on open November 4th 09/25/20 Unusually active option classes on open September 25th 08/06/20 Unusually active option classes on open August 6th AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/10/20 Largest borrow rate increases among liquid names 11/03/20 Unusually active option classes on open November 3rd 10/26/20 Unusually active option classes on open October 26th 09/09/20 Unusually active option classes on open September 9th
Conference/Events	American Association for Study of Liver Diseases to hold a virtual meeting » 04:55 11/14/20 11/14 04:55 11/14/20 04:55 ALBO Albireo Pharma $35.35 / +0.83 (+2.40%) , AZN AstraZeneca $57.37 / +0.54 (+0.95%) , BMY Bristol-Myers $63.63 / +0.88 (+1.40%) , CANF Can-Fite BioPharma $1.81 / + (+0.00%) , CBAY CymaBay $8.19 / +0.18 (+2.25%) , DNA Bought by RHHBY $0.00 / + (+0.00%) , DRRX Durect $1.79 / +0.085 (+4.99%) , ESALY Eisai $0.00 / + (+0.00%) , EXEL Exelixis $20.15 / -0.08 (-0.40%) , GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) , IVA Inventiva $14.01 / +1 (+7.69%) , MDGL Madrigal Pharmaceuticals $127.62 / +2.61 (+2.09%) , MNK Mallinckrodt $0.00 / + (+0.00%) , MRK Merck $81.10 / +1.26 (+1.58%) , MTCH Match Group $131.60 / +0.22 (+0.17%) , NVCR Novocure $124.46 / +1 (+0.81%) , RHHBY Roche $0.00 / + (+0.00%) AASLD 2020: The Virtual… AASLD 2020: The Virtual Liver Meeting will be held on November 13-16. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options RHHBY NVCR MTCH MRK MNK MDGL IVA GSK EXEL ESALY DRRX CBAY CANF BMY AZN ALBO RHHBY Roche $0.00 / + (+0.00%) 11/13/20 Halozyme: CHMP recommends EU approval of Roche's Phesgo 10/29/20 Roche receives FDA approval for cobas EGFR Mutation Test v2 10/22/20 Roche, Atea Pharmaceuticals enter agreement for exclusive rights to AT-527 10/21/20 PTC Therapeutics: Evrysdi approved in Brazil for treatment of SMA NVCR Novocure $124.46 / +1 (+0.81%) 11/11/20 Novocure receives CE Mark for NovoTTF-100L system 10/29/20 Novocure forms alliance with NYU Grossman School of Medicine 08/13/20 Novocure announces Wilco Groenhuysen as COO, other leadership promotions 07/22/20 Novocure enrolls first patient in EF-33 Phase 2 pilot trial MTCH Match Group $131.60 / +0.22 (+0.17%) 11/04/20 Match Group says future remains 'challenging to predict' 09/28/20 Match Group appoints Tracey Breeden as Head of Safety and Social Advocacy 09/03/20 Match Group says DOJ closes investigation 08/17/20 Soros boosts stakes in Alphabet, T-Mobile, takes position in Alibaba MRK Merck $81.10 / +1.26 (+1.58%) 11/13/20 FDA approves Merck's Keytruda in combination with chemo in TNBC 11/13/20 Surface announces SRF617, SRF388 to advance to combination, expansion stages 11/11/20 Xoma earns $1M milestone payment from 2018 royalty purchase agreement 11/11/20 Moderna shares interim data from mRNA-4157 with Keytruda cohort at SITC MNK Mallinckrodt $0.00 / + (+0.00%) 11/10/20 Mallinckrodt initiates NOTICE study for use of INOmax gas in COVID-19 patients 10/21/20 DOJ announces settlement agreement of over $8B with opioid maker Purdue Pharma 10/12/20 Mallinckrodt voluntarily initiates Chapter 11 proceedings in bankruptcy court 10/12/20 Mallinckrodt voluntarily initiates Chapter 11 proceedings MDGL Madrigal Pharmaceuticals $127.62 / +2.61 (+2.09%) 11/13/20 Madrigal discloses data from MAESTRO-NAFLD trial ahead of AASLD presentation 10/01/20 Madrigal announces acceptance of three abstracts for The Liver Meeting 09/03/20 Madrigal exceeds target enrollment in Phase 3 MAESTRO NAFLD-1 trial 06/29/20 Intercept plunges, drags down some NASH peers after CRL from FDA IVA Inventiva $14.01 / +1 (+7.69%) 11/10/20 Inventiva announces conclusions from phase II meeting with FDA 11/06/20 Inventiva CMO Marie-Paule Richard to retire, Michael Cooreman to succeed 11/02/20 Inventiva announces publication on role of PPARs in NASH treatment 10/19/20 Inventiva gets FDA fast track designation in MPS VI for clinical stage odiparcil GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 11/09/20 GSK's ViiV says injectable cabotegravir superior to oral SOC for HIV prevention 11/02/20 Horizon Therapeutics names Karin Rosen, M.D., Ph.D. as Chief Scientific Officer 10/28/20 Sanofi, GSK to support COVAX with 200M doses of COVID-19 vaccine 10/26/20 AnaptysBio, GlaxoSmithKline amend strategic immuno-oncology collaboration EXEL Exelixis $20.15 / -0.08 (-0.40%) 10/27/20 Exelixis announces Takeda, Ono submit application for Cabometyx in Japan 10/26/20 Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo 10/19/20 Bristol-Myers, Exelixis: FDA accepts sBLA, sNDA for OPDIVO/CABOMETYX combo 10/09/20 Exelixis, Aurigene disclose new AUR102 data at ENA Symposium ESALY Eisai $0.00 / + (+0.00%) 11/10/20 Merck reports KEYTRUDA plus LENVIMA trial met primary endpoint 11/09/20 Eisai presents latest BAN2401 data at CTAD 11/06/20 Eisai down 19% as FDA panel votes on Alzheimer's drug candidate 10/30/20 Biogen announces EMA acceptance of MAA for aducanumab DRRX Durect $1.79 / +0.085 (+4.99%) 11/13/20 Durect reports new safety data and efficacy signals from Phase 1b NASH trial 11/02/20 Durect names Dr. Norman Sussman as Chief Medical Officer 10/05/20 Durect to present results from 4-week Phase 1b clinical study of DUR-928 09/23/20 Durect doses first patient in Phase 2 DUR-928 study of COVID-19 patients CBAY CymaBay $8.19 / +0.18 (+2.25%) 11/05/20 CymaBay announces study to evaluate potential of GPR119 agonists 08/27/20 CymaBay presents final results from 52-week Phase 2 study in PBC 08/20/20 CymaBay announces presentations during Digital International Liver Conference 08/03/20 CymaBay announces topline results from ENHANCE for seladelpar CANF Can-Fite BioPharma $1.81 / + (+0.00%) 10/06/20 IDMC recommends Can-Fite BioPharma continue Comfort trial, discontinue Acrobat 08/31/20 Can-Fite BioPharma cleared by FDA to commence Phase II COVID-19 study 08/25/20 Can-Fite BioPharma granted patent from EPO for Namodenoson 07/27/20 Can-Fite BioPharma submits IND application for Phase 2 Piclidenoson study to FDA BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 11/12/20 Bristol-Myers presents outcomes in 'hard to treat' blood cancers at ASH 11/09/20 Stryker appoints Giovanni Caforio to board of directors 11/09/20 Kitov expands planned Phase 1/2 clinical trial of CM24 11/09/20 Bristol-Myers: Phase 2 study evaluating deucravacitinib met primary endpoint AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/13/20 AstraZeneca announces data from U.S. hospitalized heart failure registry 11/13/20 Ionis, AstraZeneca report efficacy and safety results of antisense medicine 11/12/20 AstraZeneca says Phase 2 Calquence COVID-19 trials didn't meet primary endpoint 11/10/20 AstraZeneca, Amgen study for severe asthma meets primary endpoint ALBO Albireo Pharma $35.35 / +0.83 (+2.40%) 11/13/20 Albireo Pharma unveils novel bile acid modulators for adult liver diseases 11/13/20 Albireo Pharma announces PEDFIC 1 meets primary, secondary endpoints 09/08/20 Albireo Pharma jumps 64% after PEDFIC 1 Phase 3 trial met endpoints 09/08/20 Albireo Pharma: PEDFIC 1 Phase 3 trial met two primary endpoints ALBO AZN BMY CANF CBAY DNA DRRX ESALY EXEL GSK IVA MDGL MNK MRK MTCH NVCR RHHBY ALBO Albireo Pharma $35.35 / +0.83 (+2.40%) 09/10/20 Cowen Albireo Pharma price target raised to $65 from $39 at Cowen 09/09/20 Guggenheim Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim 09/08/20 William Blair William Blair says Albireo data confirms 'best-in-class' profile for odevixibat 09/08/20 Jefferies Albireo Pharma price target raised to $79 from $50 at Jefferies AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/11/20 Oppenheimer Amgen price target raised to $280 from $275 at Oppenheimer 11/11/20 HSBC AstraZeneca upgraded to Hold from Reduce at HSBC 11/11/20 HSBC AstraZeneca upgraded to Hold from Reduce at HSBC 10/23/20 Stifel FibroGen safety data mitigates concerns of roxadustat black box, says Stifel BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 11/10/20 Bernstein Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein 11/10/20 Bernstein Bristol-Myers initiated with a Market Perform at Bernstein 11/06/20 Gabelli Bristol-Myers downgraded to Hold from Buy at Gabelli 11/05/20 BofA BofA sees Bristol-Myers as $80 stock, 'no reason' for shares to be down CANF Can-Fite BioPharma $1.81 / + (+0.00%) CBAY CymaBay $8.19 / +0.18 (+2.25%) 11/06/20 Raymond James CymaBay price target raised to $12 at Raymond James after Q3 report 09/25/20 Piper Sandler CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler 09/09/20 B. Riley Securities CymaBay price target raised to $13 from $9 at B. Riley FBR 08/27/20 Piper Sandler Piper Sandler 'astonished' by seladelpar's long-term benefits DNA Bought by RHHBY $0.00 / + (+0.00%) DRRX Durect $1.79 / +0.085 (+4.99%) 11/03/20 Chardan Durect Covid trial update increased interest in program, says Chardan 10/30/20 Fly Intel: Top five analyst initiations 10/30/20 Chardan Durect initiated with a Buy at Chardan 10/20/20 Cantor Fitzgerald Durect assumed with an Overweight at Cantor Fitzgerald ESALY Eisai $0.00 / + (+0.00%) 11/05/20 Jefferies Eisai upgraded to Buy from Hold at Jefferies 09/08/20 Jefferies Eisai downgraded to Hold from Buy at Jefferies EXEL Exelixis $20.15 / -0.08 (-0.40%) 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler 06/30/20 Piper Sandler Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 11/13/20 Morgan Stanley GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley 11/02/20 Liberum GlaxoSmithKline upgraded to Buy from Hold at Liberum 10/30/20 Barclays GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays 10/27/20 Truist AnaptysBio price target raised to $27 from $20 at Truist IVA Inventiva $14.01 / +1 (+7.69%) 10/13/20 Roth Capital Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation 08/17/20 H.C. Wainwright Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright 08/05/20 Fly Intel: Top five analyst initiations 08/05/20 Roth Capital Inventiva initiated with a Buy at Roth Capital MDGL Madrigal Pharmaceuticals $127.62 / +2.61 (+2.09%) 11/06/20 Goldman Sachs Madrigal Pharmaceuticals price target raised to $126 from $118 at Goldman Sachs 11/06/20 Piper Sandler Piper sees 'ideal time to buy' Madrigal Pharmaceuticals ahead of AASLD meeting 11/06/20 H.C. Wainwright Madrigal Pharmaceuticals price target raised to $184 from $165 at H.C. Wainwright 11/05/20 Piper Sandler Madrigal Pharmaceuticals price target lowered to $204 from $208 at Piper Sandler MNK Mallinckrodt $0.00 / + (+0.00%) 08/06/20 Citi Mallinckrodt price target lowered to $1 from $2 at Citi 08/05/20 BMO Capital Mallinckrodt price target lowered to $2 from $4 at BMO Capital 08/04/20 Piper Sandler Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler 07/14/20 BMO Capital Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital MRK Merck $81.10 / +1.26 (+1.58%) 11/10/20 Bernstein Bernstein bullish on Merck, initiates with an Outperform 11/10/20 Bernstein Merck initiated with an Outperform at Bernstein 11/02/20 Raymond James Jounce Therapeutics downgraded to Market Perform at Raymond James 10/23/20 Fly Intel: Pre-market Movers MTCH Match Group $131.60 / +0.22 (+0.17%) 11/10/20 Truist Match Group price target raised to $150 from $125 at Truist 11/10/20 Deutsche Bank Match Group price target raised to $160 from $150 at Deutsche Bank 11/09/20 Citi Match Group price target raised to $160 from $135 at Citi 09/24/20 Jefferies Match Group positioned to take advantage of pent up demand, says Jefferies NVCR Novocure $124.46 / +1 (+0.81%) 10/30/20 Mizuho Novocure price target raised to $150 from $84 at Mizuho 10/29/20 Piper Sandler Novocure price target raised to $140 from $125 at Piper Sandler 10/05/20 Piper Sandler Bristol-Myers approval removes some Novocure revenue upside, says Piper Sandler 09/23/20 Fly Intel: Top five analyst initiations RHHBY Roche $0.00 / + (+0.00%) 11/11/20 Truist Opthea initiated with a Buy at Truist 10/16/20 UBS Roche price target lowered to CHF 370 from CHF 390 at UBS 10/06/20 Goldman Sachs Goldman reiterates $34 target on Kiniksa after 'impressive' data 09/29/20 Berenberg Roche initiated with a Hold at Berenberg RHHBY NVCR MTCH MRK MNK MDGL GSK EXEL DRRX CBAY BMY AZN ALBO RHHBY Roche $0.00 / + (+0.00%) 10/27/20 Oncolytics announces new GI cancer study using 10/15/20 Roche confirms outlook for 2020 based on assessment of COVID-19 10/15/20 Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year 09/11/20 Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS NVCR Novocure $124.46 / +1 (+0.81%) 10/29/20 Novocure reports Q3 EPS 9c, consensus 3c 07/30/20 Novocure reports Q2 EPS 2c, consensus 0c MTCH Match Group $131.60 / +0.22 (+0.17%) 11/04/20 Match Group sees Q4 revenue $640M-$650M, consensus $622.73M 11/04/20 Match Group report Q3 EPS 45c, consensus 44c 11/04/20 Notable companies reporting after market close 08/10/20 IAC reports Q2 EPS ($1.13) vs. 16c a year ago MRK Merck $81.10 / +1.26 (+1.58%) 10/27/20 Merck raises FY20 adjusted EPS view to $5.91-$6.01 from $5.63-$5.78 10/27/20 Merck reports Q3 adjusted EPS $1.74, consensus $1.43 10/26/20 Notable companies reporting before tomorrow's open MNK Mallinckrodt $0.00 / + (+0.00%) 08/04/20 Mallinckrodt reports Q2 adj. EPS $1.89, consensus $1.34 MDGL Madrigal Pharmaceuticals $127.62 / +2.61 (+2.09%) 11/05/20 Madrigal Pharmaceuticals reports Q3 EPS ($3.75), consensus ($3.30) 08/06/20 Madrigal Pharmaceuticals reports Q2 EPS ($3.18), consensus ($2.45) GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 10/28/20 GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range 10/28/20 GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago 10/08/20 GlaxoSmithKline sees impact of foreign exchange on Q3 sales of about 5% 07/29/20 GlaxoSmithKline reports Q2 adjusted EPS 19.2p, down 37% AER EXEL Exelixis $20.15 / -0.08 (-0.40%) 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c 08/06/20 Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M 08/06/20 Exelixis reports Q2 EPS 25c, consensus 12c DRRX Durect $1.79 / +0.085 (+4.99%) 11/02/20 Durect reports Q3 EPS (5c), consensus (4c) 08/03/20 Durect reports Q2 EPS 7c, consensus 0c CBAY CymaBay $8.19 / +0.18 (+2.25%) 11/05/20 CymaBay reports Q3 EPS (17c), consensus (17c) 08/10/20 CymaBay reports Q2 EPS (16c), consensus (24c) BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 11/05/20 Bristol-Myers backs FY21 EPS view $7.15-$7.45, consensus $7.39 11/05/20 Bristol-Myers raises FY20 EPS view to $6.25-$6.35 from $6.10-$6.25 11/05/20 Bristol-Myers reports Q3 EPS $1.63, consensus $1.49 11/04/20 Notable companies reporting before tomorrow's open AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER ALBO Albireo Pharma $35.35 / +0.83 (+2.40%) 11/05/20 Albireo Pharma reports Q3 EPS ($1.96), consensus ($1.51) 08/06/20 Albireo Pharma reports Q2 EPS ($1.38), consensus ($1.69) 10 Sep 10 Jul 30 Jan 11 Dec RHHBY MTCH MRK MNK GSK BMY AZN RHHBY Roche $0.00 / + (+0.00%) 11/11/20 Roche's Franz favors COVID-19 vaccination mandate, Reuters says 10/07/20 Roche warehouse issue causes diagnostic test shipping delays, Bloomberg reports MTCH Match Group $131.60 / +0.22 (+0.17%) 09/24/20 Spotify, Match, Epic join forces to challenge App Store practices, Reuters says 08/17/20 Facebook backs Fortnite in Apple app fee battle, NY Post says 08/11/20 Match Group developing interactive features for users, WSJ reports 06/17/20 Match, Epic vocalize support for EU antitrust case against Apple, Verge says MRK Merck $81.10 / +1.26 (+1.58%) 09/24/20 Merck Covid vaccines match 'Operation Warp Speed' description, Bloomberg says 09/11/20 Merck begins testing COVID-19 vaccine in humans in phase 1/2 trial, WSJ reports MNK Mallinckrodt $0.00 / + (+0.00%) 10/21/20 Purdue Pharma to plead guilty in $8B-plus deal, AP reports 09/25/20 Mallinckrodt nearing bankruptcy filing, negotiating with key creditors, WSJ says 09/25/20 Mallinckrodt nearing bankruptcy filing over opioid suits, WSJ says GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 10/02/20 White House officials raise objections to FDA vaccine approval plans, WSJ says 10/02/20 GlaxoSmithKline verdict of $235M against Teva revived on appeal, Bloomberg says 09/23/20 U.K. to test vaccines on volunteers deliberately infected with COVID, FT reports 09/22/20 FDA to announce tougher standards for coronavirus vaccine, WaPo says BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 10/05/20 Bristol-Myers to buy MyoKardia for $13.1B, or $225/share in cash, WSJ reports 08/06/20 Trump to order government to buy certain drugs from U.S., USA Today says 07/24/20 President Trump expected to sign drug pricing executive orders, WaPo reports AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/09/20 Pfizer in talks with Brazil about selling COVID vaccine, Reuters says 11/04/20 AstraZeneca misses COVID-19 vaccine delivery target in UK, FT says 11/03/20 UK's NHS told to prepare for possible vaccine rollout as early as Dec., Sky says 10/26/20 AstraZeneca vaccine candidate shows robust immune response in elderly, FT says RHHBY MTCH MRK MNK MDGL IVA GSK EXEL ESALY DRRX CBAY BMY AZN ALBO RHHBY Roche $0.00 / + (+0.00%) 09/29/20 Hersey, Best Buy upgrades among today's top calls on Wall Street 09/23/20 Fly Intel: Wall Street's top stories for Wednesday 09/23/20 Fly Intel: Wall Street's top stories at midday 09/23/20 Regenxbio slips as Novartis' Zolgensma expansion hits FDA roadblock MTCH Match Group $131.60 / +0.22 (+0.17%) 11/04/20 Fly Intel: After-Hours Movers 09/24/20 Fly Intel: Wall Street's top stories for Thursday 09/24/20 Fly Intel: Wall Street's top stories at midday 09/03/20 Fly Intel: After-Hours Movers MRK Merck $81.10 / +1.26 (+1.58%) 10/27/20 Fly Intel: Wall Street's top stories for Tuesday 10/27/20 Fly Intel: Wall Street's top stories at midday 10/27/20 Fly Intel: Pre-market Movers MNK Mallinckrodt $0.00 / + (+0.00%) 07/15/20 Fly Intel: After-Hours Movers MDGL Madrigal Pharmaceuticals $127.62 / +2.61 (+2.09%) 11/12/20 Before the Move: Watch Madrigal Pharmaceuticals ahead of AASLD meeting IVA Inventiva $14.01 / +1 (+7.69%) 10/19/20 Fly Intel: After-Hours Movers 10/12/20 Fly Intel: After-Hours Movers GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 10/06/20 Fly Intel: Wall Street's top stories for Tuesday 10/06/20 Fly Intel: Wall Street's top stories at midday 09/19/20 Week in review: How Trump's policies moved stocks EXEL Exelixis $20.15 / -0.08 (-0.40%) 05/14/20 Allogene jumps, Compugen plunges following release of cancer meeting abstracts ESALY Eisai $0.00 / + (+0.00%) 08/07/20 Fly Intel: Wall Street's top stories at midday DRRX Durect $1.79 / +0.085 (+4.99%) 11/03/20 Fly Intel: Pre-market Movers 11/02/20 Fly Intel: After-Hours Movers 08/03/20 Fly Intel: After-Hours Movers 07/31/20 Fly Intel: Alphabet downgrade among today's top calls on Wall Street CBAY CymaBay $8.19 / +0.18 (+2.25%) 08/10/20 Fly Intel: After-Hours Movers 06/29/20 Fly Intel: Pre-market Movers BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 11/05/20 Fly Intel: Pre-market Movers 10/08/20 Cytokinetics plunges following mixed results from heart drug trial 10/05/20 Fly Intel: Wall Street's top stories for Monday 10/05/20 Fly Intel: Wall Street's top stories at midday AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/12/20 Fly Intel: Wall Street's top stories for Thursday 11/12/20 Fly Intel: Wall Street's top stories at midday 11/04/20 Fly Intel: Wall Street's top stories for Wednesday 10/23/20 Fly Intel: Wall Street's top stories for Friday ALBO Albireo Pharma $35.35 / +0.83 (+2.40%) 09/30/20 Before the Move: Watch Novo Nordisk, Bristol into AASLD abstract publication 09/08/20 Fly Intel: Wall Street's top stories at midday 12/15/20 Biopharmaceuticals/Biotech 11/17/20 West Coast Consumer Virtual Conference 11/19/20 2nd Annual Virtual Healthcare Conference 12/06/20 62nd Virtual Annual Meeting of ASH 12/08/20 Global TMT Virtual Conference 11/16/20 Inventiva - IVA 02/04/21 Merck - MRK 11/23/20 PDUFA Date for Xofluza 02/02/21 PDUFA Date for StrataGraft 02/20/21 PDUFA Date for OPDIVO / CABOMETYX bmy 03/27/21 PDUFA Date for Ide-Cel 11/23/20 Durect MTCH MRK MNK GSK DRRX CBAY BMY AZN MTCH Match Group $131.60 / +0.22 (+0.17%) 07/28/20 Match Group call volume above normal and directionally bullish 07/09/20 Unusually active option classes on open July 9th 06/23/20 Largest borrow rate increases among liquid names 06/22/20 Largest borrow rate increases among liquid names MRK Merck $81.10 / +1.26 (+1.58%) 10/20/20 Merck put volume heavy and directionally bearish 08/05/20 Merck call volume above normal and directionally bullish 08/05/20 Unusually active option classes on open August 5th MNK Mallinckrodt $0.00 / + (+0.00%) 10/13/20 Three new option listings and three option delistings on October 13th 10/08/20 Largest borrow rate increases among liquid names 08/25/20 Largest borrow rate increases among liquid names 08/20/20 Largest borrow rate increases among liquid names GSK GlaxoSmithKline $38.30 / +0.55 (+1.46%) 09/04/20 GlaxoSmithKline call volume above normal and directionally bullish 08/03/20 Unusually active option classes on open August 3rd 07/31/20 Unusually active option classes on open July 31st 07/16/20 GlaxoSmithKline put volume heavy and directionally bearish DRRX Durect $1.79 / +0.085 (+4.99%) 08/03/20 Durect options imply 25.4% move in share price post-earnings CBAY CymaBay $8.19 / +0.18 (+2.25%) 11/13/20 Largest borrow rate increases among liquid names 06/16/20 Unusual call flow in option market yesterday 06/15/20 Cymabay calls lead puts 20:1 as shares lift 10% and implied volatility BMY Bristol-Myers $63.63 / +0.88 (+1.40%) 11/04/20 Unusually active option classes on open November 4th 09/25/20 Unusually active option classes on open September 25th 08/06/20 Unusually active option classes on open August 6th AZN AstraZeneca $57.37 / +0.54 (+0.95%) 11/10/20 Largest borrow rate increases among liquid names 11/03/20 Unusually active option classes on open November 3rd 10/26/20 Unusually active option classes on open October 26th 09/09/20 Unusually active option classes on open September 9th
Conference/Events	American Association for Study of Liver Diseases to hold a virtual meeting » 08:58 11/13/20 11/13 08:58 11/13/20 08:58 ALBO Albireo Pharma $34.60 / +0.46 (+1.35%) , AZN AstraZeneca $56.84 / -1.155 (-1.99%) , BMY Bristol-Myers $62.74 / -0.68 (-1.07%) , CANF Can-Fite BioPharma $1.81 / -0.225 (-11.06%) , CBAY CymaBay $8.03 / +0.07 (+0.88%) , DNA Bought by RHHBY $0.00 / + (+0.00%) , DRRX Durect $1.71 / -0.06 (-3.40%) , ESALY Eisai $0.00 / + (+0.00%) , EXEL Exelixis $20.23 / -0.46 (-2.22%) , GSK GlaxoSmithKline $37.75 / -0.4281 (-1.12%) , IVA Inventiva $13.01 / -0.745 (-5.42%) , MDGL Madrigal Pharmaceuticals $128.00 / +1.92 (+1.52%) , MNK Mallinckrodt $0.00 / + (+0.00%) , MRK Merck $79.84 / -1.22 (-1.51%) , MTCH Match Group $131.39 / -2.04 (-1.53%) , NVCR Novocure $123.46 / +0.9 (+0.73%) , RHHBY Roche $0.00 / + (+0.00%) AASLD 2020: The Virtual… AASLD 2020: The Virtual Liver Meeting will be held on November 13-16. Webcast Link ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options RHHBY NVCR MTCH MRK MNK MDGL IVA GSK EXEL ESALY DRRX CBAY CANF BMY AZN ALBO RHHBY Roche $0.00 / + (+0.00%) 10/29/20 Roche receives FDA approval for cobas EGFR Mutation Test v2 10/22/20 Roche, Atea Pharmaceuticals enter agreement for exclusive rights to AT-527 10/21/20 PTC Therapeutics: Evrysdi approved in Brazil for treatment of SMA 10/20/20 Prothena, Roche to advance prasinezumab into late-stage clinical development NVCR Novocure $123.46 / +0.9 (+0.73%) 11/11/20 Novocure receives CE Mark for NovoTTF-100L system 10/29/20 Novocure forms alliance with NYU Grossman School of Medicine 08/13/20 Novocure announces Wilco Groenhuysen as COO, other leadership promotions 07/22/20 Novocure enrolls first patient in EF-33 Phase 2 pilot trial MTCH Match Group $131.39 / -2.04 (-1.53%) 11/04/20 Match Group says future remains 'challenging to predict' 09/28/20 Match Group appoints Tracey Breeden as Head of Safety and Social Advocacy 09/03/20 Match Group says DOJ closes investigation 08/17/20 Soros boosts stakes in Alphabet, T-Mobile, takes position in Alibaba MRK Merck $79.84 / -1.22 (-1.51%) 11/13/20 Surface announces SRF617, SRF388 to advance to combination, expansion stages 11/11/20 Xoma earns $1M milestone payment from 2018 royalty purchase agreement 11/11/20 Moderna shares interim data from mRNA-4157 with Keytruda cohort at SITC 11/10/20 Agenus: Milestone payment from Merck triggered as MK-4830 enters Phase 2 MNK Mallinckrodt $0.00 / + (+0.00%) 11/10/20 Mallinckrodt initiates NOTICE study for use of INOmax gas in COVID-19 patients 10/21/20 DOJ announces settlement agreement of over $8B with opioid maker Purdue Pharma 10/12/20 Mallinckrodt voluntarily initiates Chapter 11 proceedings in bankruptcy court 10/12/20 Mallinckrodt voluntarily initiates Chapter 11 proceedings MDGL Madrigal Pharmaceuticals $128.00 / +1.92 (+1.52%) 10/01/20 Madrigal announces acceptance of three abstracts for The Liver Meeting 09/03/20 Madrigal exceeds target enrollment in Phase 3 MAESTRO NAFLD-1 trial 06/29/20 Intercept plunges, drags down some NASH peers after CRL from FDA IVA Inventiva $13.01 / -0.745 (-5.42%) 11/10/20 Inventiva announces conclusions from phase II meeting with FDA 11/06/20 Inventiva CMO Marie-Paule Richard to retire, Michael Cooreman to succeed 11/02/20 Inventiva announces publication on role of PPARs in NASH treatment 10/19/20 Inventiva gets FDA fast track designation in MPS VI for clinical stage odiparcil GSK GlaxoSmithKline $37.75 / -0.4281 (-1.12%) 11/09/20 GSK's ViiV says injectable cabotegravir superior to oral SOC for HIV prevention 11/02/20 Horizon Therapeutics names Karin Rosen, M.D., Ph.D. as Chief Scientific Officer 10/28/20 Sanofi, GSK to support COVAX with 200M doses of COVID-19 vaccine 10/26/20 AnaptysBio, GlaxoSmithKline amend strategic immuno-oncology collaboration EXEL Exelixis $20.23 / -0.46 (-2.22%) 10/27/20 Exelixis announces Takeda, Ono submit application for Cabometyx in Japan 10/26/20 Exelixis announces 1st patient enrolled trial cohort evaluating XL092 in combo 10/19/20 Bristol-Myers, Exelixis: FDA accepts sBLA, sNDA for OPDIVO/CABOMETYX combo 10/09/20 Exelixis, Aurigene disclose new AUR102 data at ENA Symposium ESALY Eisai $0.00 / + (+0.00%) 11/10/20 Merck reports KEYTRUDA plus LENVIMA trial met primary endpoint 11/09/20 Eisai presents latest BAN2401 data at CTAD 11/06/20 Eisai down 19% as FDA panel votes on Alzheimer's drug candidate 10/30/20 Biogen announces EMA acceptance of MAA for aducanumab DRRX Durect $1.71 / -0.06 (-3.40%) 11/02/20 Durect names Dr. Norman Sussman as Chief Medical Officer 10/05/20 Durect to present results from 4-week Phase 1b clinical study of DUR-928 09/23/20 Durect doses first patient in Phase 2 DUR-928 study of COVID-19 patients 09/22/20 Durect expects 300 person alcoholic hepatitis study to begin in October CBAY CymaBay $8.03 / +0.07 (+0.88%) 11/05/20 CymaBay announces study to evaluate potential of GPR119 agonists 08/27/20 CymaBay presents final results from 52-week Phase 2 study in PBC 08/20/20 CymaBay announces presentations during Digital International Liver Conference 08/03/20 CymaBay announces topline results from ENHANCE for seladelpar CANF Can-Fite BioPharma $1.81 / -0.225 (-11.06%) 10/06/20 IDMC recommends Can-Fite BioPharma continue Comfort trial, discontinue Acrobat 08/31/20 Can-Fite BioPharma cleared by FDA to commence Phase II COVID-19 study 08/25/20 Can-Fite BioPharma granted patent from EPO for Namodenoson 07/27/20 Can-Fite BioPharma submits IND application for Phase 2 Piclidenoson study to FDA BMY Bristol-Myers $62.74 / -0.68 (-1.07%) 11/12/20 Bristol-Myers presents outcomes in 'hard to treat' blood cancers at ASH 11/09/20 Stryker appoints Giovanni Caforio to board of directors 11/09/20 Kitov expands planned Phase 1/2 clinical trial of CM24 11/09/20 Bristol-Myers: Phase 2 study evaluating deucravacitinib met primary endpoint AZN AstraZeneca $56.84 / -1.155 (-1.99%) 11/13/20 Ionis, AstraZeneca report efficacy and safety results of antisense medicine 11/12/20 AstraZeneca says Phase 2 Calquence COVID-19 trials didn't meet primary endpoint 11/10/20 AstraZeneca, Amgen study for severe asthma meets primary endpoint 11/10/20 Amgen, AstraZeneca announce NAVIGATOR trial meets primary endpoint ALBO Albireo Pharma $34.60 / +0.46 (+1.35%) 11/13/20 Albireo Pharma unveils novel bile acid modulators for adult liver diseases 11/13/20 Albireo Pharma announces PEDFIC 1 meets primary, secondary endpoints 09/08/20 Albireo Pharma jumps 64% after PEDFIC 1 Phase 3 trial met endpoints 09/08/20 Albireo Pharma: PEDFIC 1 Phase 3 trial met two primary endpoints ALBO AZN BMY CANF CBAY DNA DRRX ESALY EXEL GSK IVA MDGL MNK MRK MTCH NVCR RHHBY ALBO Albireo Pharma $34.60 / +0.46 (+1.35%) 09/10/20 Cowen Albireo Pharma price target raised to $65 from $39 at Cowen 09/09/20 Guggenheim Mirum Pharmaceuticals price target raised to $38 from $27 at Guggenheim 09/08/20 William Blair William Blair says Albireo data confirms 'best-in-class' profile for odevixibat 09/08/20 Jefferies Albireo Pharma price target raised to $79 from $50 at Jefferies AZN AstraZeneca $56.84 / -1.155 (-1.99%) 11/11/20 Oppenheimer Amgen price target raised to $280 from $275 at Oppenheimer 11/11/20 HSBC AstraZeneca upgraded to Hold from Reduce at HSBC 11/11/20 HSBC AstraZeneca upgraded to Hold from Reduce at HSBC 10/23/20 Stifel FibroGen safety data mitigates concerns of roxadustat black box, says Stifel BMY Bristol-Myers $62.74 / -0.68 (-1.07%) 11/10/20 Bernstein Bristol-Myers initiated with a Market Perform, $72 price target at Bernstein 11/10/20 Bernstein Bristol-Myers initiated with a Market Perform at Bernstein 11/06/20 Gabelli Bristol-Myers downgraded to Hold from Buy at Gabelli 11/05/20 BofA BofA sees Bristol-Myers as $80 stock, 'no reason' for shares to be down CANF Can-Fite BioPharma $1.81 / -0.225 (-11.06%) CBAY CymaBay $8.03 / +0.07 (+0.88%) 11/06/20 Raymond James CymaBay price target raised to $12 at Raymond James after Q3 report 09/25/20 Piper Sandler CymaBay beating Genfit in primary biliary cholangitis race, says Piper Sandler 09/09/20 B. Riley Securities CymaBay price target raised to $13 from $9 at B. Riley FBR 08/27/20 Piper Sandler Piper Sandler 'astonished' by seladelpar's long-term benefits DNA Bought by RHHBY $0.00 / + (+0.00%) DRRX Durect $1.71 / -0.06 (-3.40%) 11/03/20 Chardan Durect Covid trial update increased interest in program, says Chardan 10/30/20 Fly Intel: Top five analyst initiations 10/30/20 Chardan Durect initiated with a Buy at Chardan 10/20/20 Cantor Fitzgerald Durect assumed with an Overweight at Cantor Fitzgerald ESALY Eisai $0.00 / + (+0.00%) 11/05/20 Jefferies Eisai upgraded to Buy from Hold at Jefferies 09/08/20 Jefferies Eisai downgraded to Hold from Buy at Jefferies EXEL Exelixis $20.23 / -0.46 (-2.22%) 10/26/20 Piper Sandler Exelixis could have successor to Cabometyx with XL092, says Piper Sandler 09/22/20 Morgan Stanley Exelixis price target raised to $29 from $23 at Morgan Stanley 09/21/20 Piper Sandler Exelixis price target raised to $33 from $30 at Piper Sandler 06/30/20 Piper Sandler Exelixis' 2/3 Phase III Contact studies underway, says Piper Sandler GSK GlaxoSmithKline $37.75 / -0.4281 (-1.12%) 11/13/20 Morgan Stanley GlaxoSmithKline upgraded to Equal Weight from Underweight at Morgan Stanley 11/02/20 Liberum GlaxoSmithKline upgraded to Buy from Hold at Liberum 10/30/20 Barclays GlaxoSmithKline price target lowered to 1,300 GBp from 1,550 GBp at Barclays 10/27/20 Truist AnaptysBio price target raised to $27 from $20 at Truist IVA Inventiva $13.01 / -0.745 (-5.42%) 10/13/20 Roth Capital Roth backs Buy on Inventiva after Lanifibranor given breakthrough designation 08/17/20 H.C. Wainwright Inventiva price target raised to $38 from EUR 12 at H.C. Wainwright 08/05/20 Fly Intel: Top five analyst initiations 08/05/20 Roth Capital Inventiva initiated with a Buy at Roth Capital MDGL Madrigal Pharmaceuticals $128.00 / +1.92 (+1.52%) 11/06/20 Goldman Sachs Madrigal Pharmaceuticals price target raised to $126 from $118 at Goldman Sachs 11/06/20 Piper Sandler Piper sees 'ideal time to buy' Madrigal Pharmaceuticals ahead of AASLD meeting 11/06/20 H.C. Wainwright Madrigal Pharmaceuticals price target raised to $184 from $165 at H.C. Wainwright 11/05/20 Piper Sandler Madrigal Pharmaceuticals price target lowered to $204 from $208 at Piper Sandler MNK Mallinckrodt $0.00 / + (+0.00%) 08/06/20 Citi Mallinckrodt price target lowered to $1 from $2 at Citi 08/05/20 BMO Capital Mallinckrodt price target lowered to $2 from $4 at BMO Capital 08/04/20 Piper Sandler Mallinckrodt downgraded to Underweight from Neutral at Piper Sandler 07/14/20 BMO Capital Briefing docs suggest AdComm 'challenges' for Mallinckrodt, says BMO Capital MRK Merck $79.84 / -1.22 (-1.51%) 11/10/20 Bernstein Bernstein bullish on Merck, initiates with an Outperform 11/10/20 Bernstein Merck initiated with an Outperform at Bernstein 11/02/20 Raymond James Jounce Therapeutics downgraded to Market Perform at Raymond James 10/23/20 Fly Intel: Pre-market Movers MTCH Match Group $131.39 / -2.04 (-1.53%) 11/10/20 Truist Match Group price target raised to $150 from $125 at Truist 11/10/20 Deutsche Bank Match Group price target raised to $160 from $150 at Deutsche Bank 11/09/20 Citi Match Group price target raised to $160 from $135 at Citi 09/24/20 Jefferies Match Group positioned to take advantage of pent up demand, says Jefferies NVCR Novocure $123.46 / +0.9 (+0.73%) 10/30/20 Mizuho Novocure price target raised to $150 from $84 at Mizuho 10/29/20 Piper Sandler Novocure price target raised to $140 from $125 at Piper Sandler 10/05/20 Piper Sandler Bristol-Myers approval removes some Novocure revenue upside, says Piper Sandler 09/23/20 Fly Intel: Top five analyst initiations RHHBY Roche $0.00 / + (+0.00%) 11/11/20 Truist Opthea initiated with a Buy at Truist 10/16/20 UBS Roche price target lowered to CHF 370 from CHF 390 at UBS 10/06/20 Goldman Sachs Goldman reiterates $34 target on Kiniksa after 'impressive' data 09/29/20 Berenberg Roche initiated with a Hold at Berenberg RHHBY NVCR MTCH MRK MNK MDGL GSK EXEL DRRX CBAY BMY AZN ALBO RHHBY Roche $0.00 / + (+0.00%) 10/27/20 Oncolytics announces new GI cancer study using 10/15/20 Roche confirms outlook for 2020 based on assessment of COVID-19 10/15/20 Roche reports 9 months group sales CHF43.98B vs. CHF46.07B last year 09/11/20 Genentech: data shows Ocrevus 'highly effective' treatment option in RRMS NVCR Novocure $123.46 / +0.9 (+0.73%) 10/29/20 Novocure reports Q3 EPS 9c, consensus 3c 07/30/20 Novocure reports Q2 EPS 2c, consensus 0c MTCH Match Group $131.39 / -2.04 (-1.53%) 11/04/20 Match Group sees Q4 revenue $640M-$650M, consensus $622.73M 11/04/20 Match Group report Q3 EPS 45c, consensus 44c 11/04/20 Notable companies reporting after market close 08/10/20 IAC reports Q2 EPS ($1.13) vs. 16c a year ago MRK Merck $79.84 / -1.22 (-1.51%) 10/27/20 Merck raises FY20 adjusted EPS view to $5.91-$6.01 from $5.63-$5.78 10/27/20 Merck reports Q3 adjusted EPS $1.74, consensus $1.43 10/26/20 Notable companies reporting before tomorrow's open MNK Mallinckrodt $0.00 / + (+0.00%) 08/04/20 Mallinckrodt reports Q2 adj. EPS $1.89, consensus $1.34 MDGL Madrigal Pharmaceuticals $128.00 / +1.92 (+1.52%) 11/05/20 Madrigal Pharmaceuticals reports Q3 EPS ($3.75), consensus ($3.30) 08/06/20 Madrigal Pharmaceuticals reports Q2 EPS ($3.18), consensus ($2.45) GSK GlaxoSmithKline $37.75 / -0.4281 (-1.12%) 10/28/20 GlaxoSmithKline now sees 2020 adjusted EPS at lower end of down 1%-4% range 10/28/20 GlaxoSmithKline reports Q3 adjusted EPS 35.6p vs. 38.6p a year ago 10/08/20 GlaxoSmithKline sees impact of foreign exchange on Q3 sales of about 5% 07/29/20 GlaxoSmithKline reports Q2 adjusted EPS 19.2p, down 37% AER EXEL Exelixis $20.23 / -0.46 (-2.22%) 11/05/20 Exelixis sees FY20 revenue $900M-$950M, consensus $922M 11/05/20 Exelixis reports Q3 adjusted EPS 4c, consensus 1c 08/06/20 Exelixis sees FY20 revenue $900M-$950M, consensus $908.9M 08/06/20 Exelixis reports Q2 EPS 25c, consensus 12c DRRX Durect $1.71 / -0.06 (-3.40%) 11/02/20 Durect reports Q3 EPS (5c), consensus (4c) 08/03/20 Durect reports Q2 EPS 7c, consensus 0c CBAY CymaBay $8.03 / +0.07 (+0.88%) 11/05/20 CymaBay reports Q3 EPS (17c), consensus (17c) 08/10/20 CymaBay reports Q2 EPS (16c), consensus (24c) BMY Bristol-Myers $62.74 / -0.68 (-1.07%) 11/05/20 Bristol-Myers backs FY21 EPS view $7.15-$7.45, consensus $7.39 11/05/20 Bristol-Myers raises FY20 EPS view to $6.25-$6.35 from $6.10-$6.25 11/05/20 Bristol-Myers reports Q3 EPS $1.63, consensus $1.49 11/04/20 Notable companies reporting before tomorrow's open AZN AstraZeneca $56.84 / -1.155 (-1.99%) 11/05/20 AstraZeneca backs view for FY20 core EPS up by a mid- to high-teens percentage 11/05/20 AstraZeneca reports Q3 core EPS 94c, down 4% year-over-year 07/30/20 AstraZeneca backs FY20 mid- to high-teens percentage increase in core EPS 07/30/20 AstraZeneca reports Q2 core EPS 96c, up 31% at CER ALBO Albireo Pharma $34.60 / +0.46 (+1.35%) 11/05/20 Albireo Pharma reports Q3 EPS ($1.96), consensus ($1.51) 08/06/20 Albireo Pharma reports Q2 EPS ($1.38), consensus ($1.69) 10 Sep 10 Jul 30 Jan 11 Dec RHHBY MTCH MRK MNK GSK BMY AZN RHHBY Roche $0.00 / + (+0.00%) 11/11/20 Roche's Franz favors COVID-19 vaccination mandate, Reuters says 10/07/20 Roche warehouse issue causes diagnostic test shipping delays, Bloomberg reports MTCH Match Group $131.39 / -2.04 (-1.53%) 09/24/20 Spotify, Match, Epic join forces to challenge App Store practices, Reuters says 08/17/20 Facebook backs Fortnite in Apple app fee battle, NY Post says 08/11/20 Match Group developing interactive features for users, WSJ reports 06/17/20 Match, Epic vocalize support for EU antitrust case against Apple, Verge says MRK Merck $79.84 / -1.22 (-1.51%) 09/24/20 Merck Covid vaccines match 'Operation Warp Speed' description, Bloomberg says 09/11/20 Merck begins testing COVID-19 vaccine in humans in phase 1/2 trial, WSJ reports MNK Mallinckrodt $0.00 / + (+0.00%) 10/21/20 Purdue Pharma to plead guilty in $8B-plus deal, AP reports 09/25/20 Mallinckrodt nearing bankruptcy filing, negotiating with key creditors, WSJ says 09/25/20 Mallinckrodt nearing bankruptcy filing over opioid suits, WSJ says GSK GlaxoSmithKline $37.75 / -0.4281 (-1.12%) 10/02/20 White House officials raise objections to FDA vaccine approval plans, WSJ says 10/02/20 GlaxoSmithKline verdict of $235M against Teva revived on appeal, Bloomberg says 09/23/20 U.K. to test vaccines on volunteers deliberately infected with COVID, FT reports 09/22/20 FDA to announce tougher standards for coronavirus vaccine, WaPo says BMY Bristol-Myers $62.74 / -0.68 (-1.07%) 10/05/20 Bristol-Myers to buy MyoKardia for $13.1B, or $225/share in cash, WSJ reports 08/06/20 Trump to order government to buy certain drugs from U.S., USA Today says 07/24/20 President Trump expected to sign drug pricing executive orders, WaPo reports AZN AstraZeneca $56.84 / -1.155 (-1.99%) 11/09/20 Pfizer in talks with Brazil about selling COVID vaccine, Reuters says 11/04/20 AstraZeneca misses COVID-19 vaccine delivery target in UK, FT says 11/03/20 UK's NHS told to prepare for possible vaccine rollout as early as Dec., Sky says 10/26/20 AstraZeneca vaccine candidate shows robust immune response in elderly, FT says RHHBY MTCH MRK MNK MDGL IVA GSK EXEL ESALY DRRX CBAY BMY AZN ALBO RHHBY Roche $0.00 / + (+0.00%) 09/29/20 Hersey, Best Buy upgrades among today's top calls on Wall Street 09/23/20 Fly Intel: Wall Street's top stories for Wednesday 09/23/20 Fly Intel: Wall Street's top stories at midday 09/23/20 Regenxbio slips as Novartis' Zolgensma expansion hits FDA roadblock MTCH Match Group $131.39 / -2.04 (-1.53%) 11/04/20 Fly Intel: After-Hours Movers 09/24/20 Fly Intel: Wall Street's top stories for Thursday 09/24/20 Fly Intel: Wall Street's top stories at midday 09/03/20 Fly Intel: After-Hours Movers MRK Merck $79.84 / -1.22 (-1.51%) 10/27/20 Fly Intel: Wall Street's top stories for Tuesday 10/27/20 Fly Intel: Wall Street's top stories at midday 10/27/20 Fly Intel: Pre-market Movers MNK Mallinckrodt $0.00 / + (+0.00%) 07/15/20 Fly Intel: After-Hours Movers MDGL Madrigal Pharmaceuticals $128.00 / +1.92 (+1.52%) 11/12/20 Before the Move: Watch Madrigal Pharmaceuticals ahead of AASLD meeting IVA Inventiva $13.01 / -0.745 (-5.42%) 10/19/20 Fly Intel: After-Hours Movers 10/12/20 Fly Intel: After-Hours Movers GSK GlaxoSmithKline $37.75 / -0.4281 (-1.12%) 10/06/20 Fly Intel: Wall Street's top stories for Tuesday 10/06/20 Fly Intel: Wall Street's top stories at midday 09/19/20 Week in review: How Trump's policies moved stocks EXEL Exelixis $20.23 / -0.46 (-2.22%) 05/14/20 Allogene jumps, Compugen plunges following release of cancer meeting abstracts ESALY Eisai $0.00 / + (+0.00%) 08/07/20 Fly Intel: Wall Street's top stories at midday DRRX Durect $1.71 / -0.06 (-3.40%) 11/03/20 Fly Intel: Pre-market Movers 11/02/20 Fly Intel: After-Hours Movers 08/03/20 Fly Intel: After-Hours Movers 07/31/20 Fly Intel: Alphabet downgrade among today's top calls on Wall Street CBAY CymaBay $8.03 / +0.07 (+0.88%) 08/10/20 Fly Intel: After-Hours Movers 06/29/20 Fly Intel: Pre-market Movers BMY Bristol-Myers $62.74 / -0.68 (-1.07%) 11/05/20 Fly Intel: Pre-market Movers 10/08/20 Cytokinetics plunges following mixed results from heart drug trial 10/05/20 Fly Intel: Wall Street's top stories for Monday 10/05/20 Fly Intel: Wall Street's top stories at midday AZN AstraZeneca $56.84 / -1.155 (-1.99%) 11/12/20 Fly Intel: Wall Street's top stories for Thursday 11/12/20 Fly Intel: Wall Street's top stories at midday 11/04/20 Fly Intel: Wall Street's top stories for Wednesday 10/23/20 Fly Intel: Wall Street's top stories for Friday ALBO Albireo Pharma $34.60 / +0.46 (+1.35%) 09/30/20 Before the Move: Watch Novo Nordisk, Bristol into AASLD abstract publication 09/08/20 Fly Intel: Wall Street's top stories at midday 12/15/20 Biopharmaceuticals/Biotech 11/14/20 AASLD 2020: The Liver Meeting 11/17/20 West Coast Consumer Virtual Conference 11/19/20 2nd Annual Virtual Healthcare Conference 12/06/20 62nd Virtual Annual Meeting of ASH 12/08/20 Global TMT Virtual Conference 11/16/20 Inventiva - IVA 02/04/21 Merck - MRK 11/23/20 PDUFA Date for Xofluza 02/02/21 PDUFA Date for StrataGraft 02/20/21 PDUFA Date for OPDIVO / CABOMETYX bmy 03/27/21 PDUFA Date for Ide-Cel MTCH MRK MNK GSK DRRX CBAY BMY AZN MTCH Match Group $131.39 / -2.04 (-1.53%) 07/28/20 Match Group call volume above normal and directionally bullish 07/09/20 Unusually active option classes on open July 9th 06/23/20 Largest borrow rate increases among liquid names 06/22/20 Largest borrow rate increases among liquid names MRK Merck $79.84 / -1.22 (-1.51%) 10/20/20 Merck put volume heavy and directionally bearish 08/05/20 Merck call volume above normal and directionally bullish 08/05/20 Unusually active option classes on open August 5th MNK Mallinckrodt $0.00 / + (+0.00%) 10/13/20 Three new option listings and three option delistings on October 13th 10/08/20 Largest borrow rate increases among liquid names 08/25/20 Largest borrow rate increases among liquid names 08/20/20 Largest borrow rate increases among liquid names GSK GlaxoSmithKline $37.75 / -0.4281 (-1.12%) 09/04/20 GlaxoSmithKline call volume above normal and directionally bullish 08/03/20 Unusually active option classes on open August 3rd 07/31/20 Unusually active option classes on open July 31st 07/16/20 GlaxoSmithKline put volume heavy and directionally bearish DRRX Durect $1.71 / -0.06 (-3.40%) 08/03/20 Durect options imply 25.4% move in share price post-earnings CBAY CymaBay $8.03 / +0.07 (+0.88%) 11/13/20 Largest borrow rate increases among liquid names 06/16/20 Unusual call flow in option market yesterday 06/15/20 Cymabay calls lead puts 20:1 as shares lift 10% and implied volatility 05/13/20 Unusually active option classes on open May 13th BMY Bristol-Myers $62.74 / -0.68 (-1.07%) 11/04/20 Unusually active option classes on open November 4th 09/25/20 Unusually active option classes on open September 25th 08/06/20 Unusually active option classes on open August 6th AZN AstraZeneca $56.84 / -1.155 (-1.99%) 11/10/20 Largest borrow rate increases among liquid names 11/03/20 Unusually active option classes on open November 3rd 10/26/20 Unusually active option classes on open October 26th 09/09/20 Unusually active option classes on open September 9th

On The Fly

News and insights, exclusive to thefly.com

No On The Fly News for your search

View all On The Fly Stories »

Upcoming
Events (10)

	Western Institutional Investor Virtual Conference
	China Automotive & Industrialo Access Days Virtual Conference
AGN ...	Aesthetics Tech Virtual Summit 2021
	2021 VESS Annual Winter Meeting
VSTO ...	Virtual Outdoor Day
	2021 Conservation Finance Virtual Conference
	Oncology Investor Virtual Conference
DM	Desktop Metal
AR	Antero Resources
TOSBF	Toshiba, also use TOSYY

View all of today’s events »

Today’s
Syndicate (15)

DFH	IPO
MYTE	IPO
RLX	IPO
ATHA	Secondary
CDNA	Secondary
CMRX	Secondary
CTMX	Secondary
CYRX	Secondary
DYN	Secondary
EDIT	Secondary
MRUS	Secondary
CYRX	Spot Secondary
INO	Spot Secondary
ONCS	Spot Secondary
ORC	Spot Secondary

View this week’s syndicate »

Get Full Fly Access

Breaking market intelligence sent straight to you: Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.

Up-to-date information on important industry events: Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.

News focused on the companies in your portfolio: Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.

14 Day Free Trial